


JOINT INVENTORS

"EXPRESS MAIL" mailing label

No. EL026011853US.

Date of Deposit: July 21, 1998.

I hereby certify that this paper (or fee) is being deposited with the United States Postal Service "EXPRESS MAIL POST OFFICE TO ADDRESSEE" service under 37 CFR §1.10 on the date indicated above and is addressed to: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231

  
Jeffrey D. Hsi, Ph.D.  
Reg. No. 40,024

APPLICATION FOR  
UNITED STATES LETTERS PATENT

S P E C I F I C A T I O N

-----  
Attorney's Docket No. 11021US03 / 100-238.C1

TO ALL WHOM IT MAY CONCERN:

Be it known that we, ROGER G. LITTLE, II, a citizen of the United States, residing at 620 Rose Drive, Benicia, and State of California 94510, and EDWARD LIM, a citizen of the United States residing at 1480 Creekside Drive, #A-302, Walnut Creek, and State of California 94596, and MITCHELL B. FADEM, a citizen of the United States residing at 8 Miramonte Road, Carmel Valley, and State of California 93924, have invented new and useful ANTI-FUNGAL PEPTIDES, of which the following is a specification.

100-238.C1

## ANTI-FUNGAL PEPTIDES

5

This is a continuation of U.S. Patent Application No. 08/504,841 filed July 20, 1995, which is herein incorporated by reference.

### BACKGROUND OF INVENTION

10

The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides.

15

BPI is a protein isolated from the granules of mammalian polymorphonuclear leukocytes (PMNs or neutrophils), which are blood cells essential in the defense against invading microorganisms. Human BPI protein has been isolated from PMNs by acid extraction combined with either ion exchange chromatography [Elsbach, *J. Biol. Chem.*, 254:11000 (1979)] or *E. coli* affinity chromatography [Weiss, et al, *Blood*, 69:652 (1987)]. BPI obtained in such a manner is referred to herein as natural BPI and has been shown to have potent bactericidal activity against a broad spectrum of gram-negative bacteria. The molecular weight of human BPI is approximately 55,000 daltons (55 kD). The amino acid sequence of the entire human BPI protein and the nucleic acid sequence of DNA encoding the protein have been

20  
25

reported in Figure 1 of Gray et al., *J. Biol. Chem.*, 264:9505 (1989), incorporated herein by reference. The Gray et al. DNA and amino acid sequences are set out in SEQ ID NOS: 205 and 206 hereto.

BPI is a strongly cationic protein. The N-terminal half of BPI  
 5 accounts for the high net positive charge; the C-terminal half of the molecule has a net charge of -3. [Elsbach and Weiss (1981), *supra*.] A proteolytic N-terminal fragment of BPI having a molecular weight of about 25 kD has an amphipathic character, containing alternating hydrophobic and hydrophilic regions. This N-terminal fragment of human BPI possesses the anti-bacterial  
 10 efficacy of the naturally-derived 55 kD human BPI holoprotein. [Ooi et al., *J. Bio. Chem.*, 262: 14891-14894 (1987)]. In contrast to the N-terminal portion, the C-terminal region of the isolated human BPI protein displays only slightly detectable anti-bacterial activity against gram-negative organisms. [Ooi et al., *J. Exp. Med.*, 174:649 (1991).] An N-terminal BPI fragment of  
 15 approximately 23 kD, referred to as "rBPI<sub>23</sub>," has been produced by recombinant means and also retains anti-bacterial activity against gram-negative organisms [Gazzano-Santoro et al., *Infect. Immun.* 60:4754-4761 (1992)]. In that publication, an expression vector was used as a source of DNA encoding a recombinant expression product (rBPI<sub>23</sub>). The vector was  
 20 constructed to encode the 31-residue signal sequence and the first 199 amino acids of the N-terminus of the mature human BPI, as set out in SEQ ID NOS: 205 and 206 taken from Gray et al., *supra*, except that valine at position 151 is specified by GTG rather than GTC and residue 185 is glutamic acid (specified by GAG) rather than lysine (specified by AAG). Recombinant  
 25 holoprotein, also referred to as rBPI, has also been produced having the sequence set out in SEQ ID NOS: 205 and 206 taken from Gray et al., *supra*, with the exceptions noted for rBPI<sub>23</sub>. An N-terminal fragment analog designated rBPI<sub>21</sub> or rBPI<sub>21</sub>Δcys has been described in co-owned, copending U.S. Patent No. 5,420,019 which is incorporated herein by reference. This  
 30 analog comprises the first 193 amino acids of BPI holoprotein as set out in

SEQ ID NOS: 205 and 206 but wherein the cysteine at residue number 132 is substituted with alanine, and with the exceptions noted for rBPI<sub>23</sub>.

The bactericidal effect of BPI has been reported to be highly specific to gram-negative species, e.g., in Elsbach and Weiss, *Inflammation: Basic Principles and Clinical Correlates*, eds. Gallin et al., Chapter 30, Raven Press, Ltd. (1992). BPI is commonly thought to be non-toxic for other microorganisms, including yeast, and for higher eukaryotic cells. Elsbach and Weiss (1992), *supra*, reported that BPI exhibits anti-bacterial activity towards a broad range of gram-negative bacteria at concentrations as low as  $10^{-8}$  to  $10^{-9}$  M, but that 100- to 1,000-fold higher concentrations of BPI were non-toxic to all of the gram-positive bacterial species, yeasts, and higher eukaryotic cells tested at that time. It was also reported that BPI at a concentration of  $10^{-6}$  M or 160  $\mu$ g/ml had no toxic effect, when tested at a pH of either 7.0 or 5.5, on the gram-positive organisms *Staphylococcus aureus* (four strains), *Staphylococcus epidermidis*, *Streptococcus faecalis*, *Bacillus subtilis*, *Micrococcus lysodeikticus*, and *Listeria monocytogenes*. BPI at  $10^{-6}$  M reportedly had no toxic effect on the fungi *Candida albicans* and *Candida parapsilosis* at pH 7.0 or 5.5, and was non-toxic to higher eukaryotic cells such as human, rabbit and sheep red blood cells and several human tumor cell lines. See also Elsbach and Weiss, *Advances in Inflammation Research*, ed. G. Weissmann, Vol. 2, pages 95-113 Raven Press (1981). This reported target cell specificity was believed to be the result of the strong attraction of BPI for lipopolysaccharide (LPS), which is unique to the outer membrane (or envelope) of gram-negative organisms.

The precise mechanism by which BPI kills gram-negative bacteria is not yet completely elucidated, but it is believed that BPI must first bind to the surface of the bacteria through hydrophobic and electrostatic interactions between the cationic BPI protein and negatively charged sites on LPS. LPS has been referred to as "endotoxin" because of the potent inflammatory response that it stimulates, *i.e.*, the release of mediators by host

inflammatory cells which may ultimately result in irreversible endotoxic shock. BPI binds to lipid A, reported to be the most toxic and most biologically active component of LPS.

In susceptible gram-negative bacteria, BPI binding is thought to disrupt LPS structure, leading to activation of bacterial enzymes that degrade phospholipids and peptidoglycans, altering the permeability of the cell's outer membrane, and initiating events that ultimately lead to cell death. [Elsbach and Weiss (1992), *supra*]. BPI is thought to act in two stages. The first is a sublethal stage that is characterized by immediate growth arrest, permeabilization of the outer membrane and selective activation of bacterial enzymes that hydrolyze phospholipids and peptidoglycans. Bacteria at this stage can be rescued by growth in serum albumin supplemented media [Mannion et al., *J. Clin. Invest.*, 85:853-860 (1990)]. The second stage, defined by growth inhibition that cannot be reversed by serum albumin, occurs after prolonged exposure of the bacteria to BPI and is characterized by extensive physiologic and structural changes, including apparent damage to the inner cytoplasmic membrane.

Initial binding of BPI to LPS leads to organizational changes that probably result from binding to the anionic groups in the KDO region of LPS, which normally stabilize the outer membrane through binding of  $Mg^{++}$  and  $Ca^{++}$ . Attachment of BPI to the outer membrane of gram-negative bacteria produces rapid permeabilization of the outer membrane to hydrophobic agents such as actinomycin D. Binding of BPI and subsequent gram-negative bacterial killing depends, at least in part, upon the LPS polysaccharide chain length, with long O-chain bearing, "smooth" organisms being more resistant to BPI bactericidal effects than short O-chain bearing, "rough" organisms [Weiss et al., *J. Clin. Invest.* 65: 619-628 (1980)]. This first stage of BPI action, permeabilization of the gram-negative outer envelope, is reversible upon dissociation of the BPI, a process requiring the presence of divalent cations and synthesis of new LPS [Weiss et al., *J.*

*Immunol.* 132: 3109-3115 (1984)]. Loss of gram-negative bacterial viability, however, is not reversed by processes which restore the envelope integrity, suggesting that the bactericidal action is mediated by additional lesions induced in the target organism and which may be situated at the cytoplasmic membrane [Mannion et al., *J. Clin. Invest.* 86: 631-641 (1990)]. Specific investigation of this possibility has shown that on a molar basis BPI is at least as inhibitory of cytoplasmic membrane vesicle function as polymyxin B [In't Veld et al., *Infection and Immunity* 56: 1203-1208 (1988)] but the exact mechanism as well as the relevance of such vesicles to studies of intact organisms has not yet been elucidated.

Three separate functional domains within the recombinant 23 kD N-terminal BPI sequence have been discovered [Little et al., *J. Biol. Chem.* 269: 1865 (1994)]. These functional domains of BPI designate a region of the amino acid sequence of BPI that contributes to the total biological activity of the protein and were essentially defined by the activities of proteolytic cleavage fragments, overlapping 15-mer peptides and other synthetic peptides. Domain I is defined as the amino acid sequence of BPI comprising from about amino acid 17 to about amino acid 45. Peptides based on this domain are moderately active in both the inhibition of LPS-induced LAL activity and in heparin binding assays, and do not exhibit significant bactericidal activity. Domain II is defined as the amino acid sequence of BPI comprising from about amino acid 65 to about amino acid 99. Peptides based on this domain exhibit high LPS and heparin binding capacity and are bactericidal. Domain III is defined as the amino acid sequence of BPI comprising from about amino acid 142 to about amino acid 169. Peptides based on this domain exhibit high LPS and heparin binding activity and are bactericidal. The biological activities of functional domain peptides may include LPS binding, LPS neutralization, heparin binding, heparin neutralization or bactericidal activity.

Fungi are eukaryotic cells that may reproduce sexually or asexually and may be biphasic, with one form in nature and a different form in the infected host. Fungal diseases are referred to as mycoses. Some mycoses are endemic, i.e. infection is acquired in the geographic area that is the natural habitat of that fungus. These endemic mycoses are usually self-limited and minimally symptomatic. Some mycoses are chiefly opportunistic, occurring in immunocompromised patients such as organ transplant patients, cancer patients undergoing chemotherapy, burn patients, AIDS patients, or patients with diabetic ketoacidosis.

Fungal infections are becoming a major health concern for a number of reasons, including the limited number of anti-fungal agents available, the increasing incidence of species resistant to older anti-fungal agents, and the growing population of immunocompromised patients at risk for opportunistic fungal infections. The incidence of systemic fungal infections increased 600% in teaching hospitals and 220% in non-teaching hospitals during the 1980's. The most common clinical isolate is *Candida albicans* (comprising about 19% of all isolates). In one study, nearly 40% of all deaths from hospital-acquired infections were due to fungi. [Sternberg, *Science*, 266:1632-1634 (1994).]

Anti-fungal agents include three main groups. The major group includes polyene derivatives, including amphotericin B and the structurally related compounds nystatin and pimaricin. These are broad-spectrum anti-fungals that bind to ergosterol, a component of fungal cell membranes, and thereby disrupt the membranes. Amphotericin B is usually effective for systemic mycoses, but its administration is limited by toxic effects that include fever and kidney damage, and other accompanying side effects such as anemia, low blood pressure, headache, nausea, vomiting and phlebitis. The unrelated anti-fungal agent flucytosine (5-fluorocytosine), an orally absorbed drug, is frequently used as an adjunct to amphotericin B treatment for some



forms of candidiasis and cryptococcal meningitis. Its adverse effects include bone marrow depression with leukopenia and thrombocytopenia.

The second major group of anti-fungal agents includes azole derivatives which impair synthesis of ergosterol and lead to accumulation of metabolites that disrupt the function of fungal membrane-bound enzyme systems (e.g., cytochrome P450) and inhibit fungal growth. Significant inhibition of mammalian P450 results in significant drug interactions. This group of agents includes ketoconazole, clotrimazole, miconazole, econazole, butoconazole, oxiconazole, sulconazole, terconazole, fluconazole and itraconazole. These agents may be administered to treat systemic mycoses. Ketoconazole, an orally administered imidazole, is used to treat nonmeningeal blastomycosis, histoplasmosis, coccidioidomycosis and paracoccidioidomycosis in non-immunocompromised patients, and is also useful for oral and esophageal candidiasis. Adverse effects include rare drug-induced hepatitis; ketoconazole is also contraindicated in pregnancy. Itraconazole appears to have fewer side effects than ketoconazole and is used for most of the same indications. Fluconazole also has fewer side effects than ketoconazole and is used for oral and esophageal candidiasis and cryptococcal meningitis. Miconazole is a parenteral imidazole with efficacy in coccidioidomycosis and several other mycoses, but has side effects including hyperlipidemia and hyponatremia.

The third major group of anti-fungal agents includes allylamines-thiocarbamates, which are generally used to treat skin infections.

This group includes tolnaftate and naftifine.

Another anti-fungal agent is griseofulvin, a fungistatic agent which is administered orally for fungal infections of skin, hair or nails that do not respond to topical treatment.

Most endemic mycoses are acquired by the respiratory route and are minimally symptomatic; cough, fever, headache, and pleuritic pain may be seen. Occasionally, endemic mycoses may cause progressive



pulmonary disease or systemic infection. Histoplasmosis, caused by *Histoplasma*, is the most common endemic respiratory mycosis in the United States; over 40 million people have been infected. The disease is noncontagious and ordinarily self-limited, but chronic pulmonary infection and disseminated infection may occur. Pulmonary infection rarely requires treatment, but disseminated infection may be treated with amphotericin B. Coccidioidomycosis, caused by *Coccidioides*, is a noncontagious respiratory mycosis prevalent in the southwest United States. It also is usually self-limited but may lead to chronic pulmonary infection or disseminated infection. Amphotericin B or miconazole may be given for treatment. Blastomycosis, caused by *Blastomyces* is a noncontagious, subacute or chronic endemic mycosis most commonly seen in the southeast United States. Most pulmonary infections are probably self-limited. Patients with progressive lung disease or disseminated disease, and immunocompromised patients, may be treated systemically with amphotericin B. Paracoccidioidomycosis, caused by *Paracoccidioides*, is a noncontagious respiratory mycosis that is the most common systemic mycosis in South America. It may be acute and self-limited or may produce progressive pulmonary disease or extrapulmonary dissemination. Disseminated disease is generally fatal in the absence of therapy. Sulfonamides may be used but have a low success rate. Amphotericin B produces a higher response rate but relapses may still occur.

Cryptococcosis is a noncontagious, often opportunistic mycosis. It is characterized by respiratory involvement or hematogenous dissemination, often with meningitis. A major etiologic agent is *C. neoformans*. Most pulmonary infections are probably overlooked, but cryptococcal meningitis, which accounts for 90% of reported disease, is dramatic and seldom overlooked. Cryptococcosis is a particular problem in immunocompromised patients; cryptococcal meningitis occurs in 7 to 10% of AIDS patients. The principal symptom of meningitis is headache; associated findings include mental changes, ocular symptoms, hearing deficits, nausea, vomiting, and

seizures. Without treatment, 80% of patients die within two years. In meningitis, cryptococci can be observed in India ink preparations of cerebrospinal fluid sediment, and can be cultured from the cerebrospinal fluid. Treatment is generally with fluconazole or the combination of amphotericin B and flucytosine, although amphotericin B does not cross the blood brain barrier.

Aspergillosis is a term that encompasses a variety of disease processes caused by *Aspergillus* species. *Aspergillus* species are ubiquitous; their spores are constantly being inhaled. Of the more than 300 species known, only a few are ordinarily pathogenic for man: *A. fumigatus*, *A. flavus*, *A. niger*, *A. nidulans*, *A. terreus*, *A. sydowi*, *A. flavatus*, and *A. glaucus*. Aspergillosis is increasing in prevalence and is particularly a problem among patients with chronic respiratory disease or immunocompromised patients. Among immunocompromised patients, aspergillosis is second only to candidiasis as the most common opportunistic mycosis and accounts for about 15% of the systemic mycoses in this group. Opportunistic pulmonary aspergillosis is characterized by widespread bronchial erosion and ulceration, followed by invasion of the pulmonary vessels, with thrombosis, embolization and infarction. Clinically, infection manifests as a necrotizing patchy bronchopneumonia, sometimes with hemorrhagic pulmonary infarction. In about 40% of cases, there is hematogenous spread to other sites. Aspergillosis is also a rare but devastating complication of burn wounds; amputation is often required for cure. Invasive aspergillosis is commonly fatal, so aggressive diagnosis and treatment is required. Blood, urine and cerebrospinal fluid cultures are rarely positive, but fungi can be seen in smears and biopsies. Amphotericin B can be given for treatment.

Mucormycosis is an acute suppurative opportunistic mycosis that produces rhinocerebral, pulmonary or disseminated disease in immunocompromised patients, and local or disseminated disease in patients with burns or open wounds. Infection is caused by fungi in the class Zygomycetes, and

include *Basidiobolus*, *Conidiobolus*, *Rhizopus*, *Mucor*, *Absidia*, *Mortierella*, *Cunninghamella*, and *Saksenaea*. Rhinocerebral mucormycosis accounts for about half of all cases of mucormycosis. It is one of the most rapidly fatal fungal diseases, with death occurring within 2-10 days in untreated patients.

5 Early clinical signs include nasal stuffiness, bloody nasal discharge, facial swelling and facial pain. The infection then spreads to the eyes, cranial nerves and brain. Pulmonary mucormycosis is nearly as common as rhinocerebral disease and manifests with the same necrotizing and infarction as aspergillosis. Fungi are virtually never seen or cultured from blood,  
10 sputum or cerebrospinal fluid. Disseminated mucormycosis may follow pulmonary or burn wound infection. Treatment is with amphotericin B.

Candidiasis is a general term for a variety of local and systemic processes caused by colonization or infection of the host by species of the yeast *Candida*. Candidiasis occurs worldwide; superficial infections of the  
15 skin, mouth and other mucus membranes are universal. Invasive systemic disease has become a problem due to the use of high doses of antibiotics that destroy normal bacterial flora, immunosuppressive agents, and agents toxic to bone marrow, *e.g.*, during cancer therapy. Neutropenia is a major risk factor for *Candida* dissemination. Candidiasis is also seen among  
20 immunocompromised individuals such as AIDS patients, organ transplant patients, patients receiving parenteral nutrition, and cancer patients undergoing radiation treatment and chemotherapy. It is the most common opportunistic mycosis in the world. The most common etiologic agent is *Candida albicans*. Other infectious species include *C. tropicalis*, *C. parapsilosis*, *C. stellatoidea*,  
25 *C. krusei*, *C. parakrusei*, *C. lusitaniae*, *C. pseudotropicalis*, *C. guilliermondi* and *C. glabrata*. *Candida albicans* is normally found in the mouth, throat, gastrointestinal tract and vagina of humans. Non-*albicans* species frequently colonize skin. *Candida* species occur in two forms that are not temperature- or host-dependent. The usual colonizing forms are yeasts that may assume a  
30 pseudomycelial configuration, especially during tissue invasion.

Pseudomyceliae result from the sequential budding of yeasts into branching chains of elongated organisms.

*Candida albicans* contains cell wall mannoproteins that appear to be responsible for attachment of the yeast cells to specific host tissues. It has been reported that the mannan portion, rather than the protein portion, of the mannoproteins is responsible for adherence of fungal cells to spleen and lymph node tissues in mice. [Kanbe et al., *Infection Immunity*, 61:2578-2584 (1993).]

*C. albicans* also binds avidly to extracellular matrix (ECM) proteins such as fibronectin, laminin, and types I and IV collagen, all of which contain heparin-binding domains. This suggests *C. albicans* may express a heparin-like surface molecule. Adherence of *C. albicans* to the ECM may be important in the pathogenesis of disseminated candidiasis. It has been demonstrated that heparin, heparan sulfate and dextran sulfate glycosaminoglycans (GAGs) inhibit adherence of *C. albicans* to ECM and ECM proteins, possibly by a mechanism involving binding of GAGs to ECM proteins, thus masking these selective ligands. [Klotz et al., *FEMS Microbiology Letters*, 78:205-208 (1992).]

Clinically, candidiasis manifests as superficial mucocutaneous infections, chronic mucocutaneous candidiasis, or systemic infection. Superficial mucocutaneous infections can occur in any area of skin or mucus membrane. Thrush, commonly seen in AIDS patients, is characterized by a patchy or continuous, creamy to gray pseudomembrane that covers the tongue, mouth, or other oropharyngeal surfaces and may be accompanied by ulceration and necrosis. Laryngeal involvement results in hoarseness. Esophagitis is often an extension of oropharyngeal disease and may manifest with symptoms of retrosternal pain and dysphagia. Intestinal candidiasis is commonly asymptomatic, but is a major source of hematogenous invasion in immunocompromised individuals. Intertrigo involves the axillae, groins, inframammary folds, and other warm, moist areas, and may manifest as red,

oozing or dry, scaly lesions. Infections may occur in other areas, including perianal and genital areas. Paronychia, infection of the nails, often follows chronic exposure of the hands or feet to moisture. Some patients with limited T-cell immunodeficiency develop chronic mucocutaneous candidiasis. These patients suffer from persistent superficial *Candida* infection of the skin, scalp, nails and mucus membranes.

Most cases of systemic candidiasis are caused by *Candida albicans* and *C. tropicalis*, and increasingly, *C. glabrata*. Clinical manifestations of *Candida* infection appear mainly in the eyes, kidneys and skin. In the eyes, there may be single or multiple raised, white, fluffy chorioretinal lesions. These lesions are a potential cause of blindness. Involvement of the kidneys includes diffuse abscesses, capillary necrosis and obstruction of the ureters. Infection may result in progressive renal insufficiency. Systemic *Candida* infection can also manifest as maculonodular skin lesions surrounded by a reddened area; these lesions have an appearance similar to acne but are a major clue to a potentially lethal disease. Other manifestations of systemic candidiasis may include osteomyelitis, arthritis, meningitis, and abscesses in the brain, heart, liver, spleen and thyroid. Involvement of the lungs is also common, but pulmonary lesions are usually too small to be seen on chest X-ray. Finally, *Candida* endocarditis can occur in patients receiving prolonged intravenous therapy or cardiac valve implants, or in intravenous drug abusers. Fungal lesions appear on the valves, and can embolize and occlude large blood vessels.

Superficial infections are diagnosed by microscopic examination of scrapings or swabs of infected lesions in the presence of 10% potassium hydroxide. *Candida* organisms can also be seen on gram stain. Endocarditis is diagnosed by blood cultures or demonstration of bulky valvular lesions on echocardiography. Systemic candidiasis may be difficult to diagnose because the presence of heavy colonization at the usual sites of infection indicates, but does not prove, that dissemination has occurred. The most reliable evidence

of systemic candidiasis is biopsy demonstration of tissue invasion or recovery of yeast from fluid in a closed body cavity, such as cerebral spinal fluid, pleural or peritoneal fluid. Similarly, positive blood or urine or sputum cultures may indicate invasive disease or simply localized disease around  
 5 indwelling devices, *e.g.*, catheters or intravenous lines.

Mucocutaneous infections may be treated with topical preparations of nystatin, amphotericin B, clotrimazole, miconazole, haloprogin or gentian violet. Oropharyngeal or esophageal candidiasis can be treated with systemic agents such as ketoconazole or fluconazole. Chronic  
 10 mucocutaneous candidiasis syndrome may respond to topical or systemic therapeutic agents such as amphotericin B or ketoconazole, but often relapses when medication is discontinued. Cystitis may be treated with amphotericin B bladder rinses, or a brief low-dose intravenous course of amphotericin B with or without oral flucytosine. Endocarditis is essentially incurable without  
 15 valve replacement, accompanied by a 6 to 10 week course of amphotericin B and flucytosine. Even with therapy, however, complete cure of endocarditis is not always possible.

The mortality rate from systemic candidiasis is about 50%. Systemic candidiasis may be treated with fluconazole, a fungistatic agent, or  
 20 amphotericin B, a fungicidal agent although systemic use of the latter is limited by its toxicity. Both drugs have substantial adverse reactions when used in combination with cyclosporine A, which itself can be nephrotoxic. The removal of precipitating factors such as intravenous lines or catheters is  
 also important for controlling infection. Flucytosine therapy can be added to  
 25 the amphotericin B therapy for treatment of systemic candidiasis, especially in patients that are not immunocompromised. In immunocompromised patients, however, these infections are problematic and resist effective treatment. Mortality with systemic candidiasis can be over 90% in such patients. Furthermore, chronic mucocutaneous candidiasis and candidal



endocarditis often show evidence of disease after having been declared cured.

There continues to exist a need in the art for new anti-fungal methods and materials. In particular, effective anti-fungal therapy for systemic mycoses is limited. Products and methods responsive to this need would ideally involve substantially non-toxic compounds available in large quantities by means of synthetic or recombinant methods. Ideal compounds would have a rapid effect and a broad spectrum of fungicidal or fungistatic activity against a variety of different fungal species when administered or applied as the sole anti-fungal agent. Ideal compounds would also be useful in combinative therapies with other anti-fungal agents, particularly where these activities would reduce the amount of anti-fungal agent required for therapeutic effectiveness, enhance the effect of such agents, or limit potential toxic responses and high cost of treatment.

#### SUMMARY OF THE INVENTION

The present invention provides novel peptides derived from or based on Domain III (amino acids 142-169) of bactericidal/permeability-increasing protein (BPI) and therapeutic uses of such peptides as anti-fungal agents. Peptides of the invention are useful in methods of treating a subject suffering from a fungal infection by administering a therapeutically effective amount of the peptide. This is based on the surprising discovery that Domain III derived peptides have fungicidal/fungistatic effects. A second surprising discovery is that such peptides have LPS-neutralizing activity. This activity provides an additional benefit in the use of peptides of the invention for treating fungal infections. Domain III derived peptides may be administered alone or in conjunction with known anti-fungal agents. When made the subject of adjunctive therapy, the administration of Domain III derived peptides may reduce the amount of anti-fungal agent needed for effective therapy, thus limiting potential toxic response and/or high cost of treatment.



Administration of Domain III derived peptides may also enhance the effect of such agents, accelerate the effect of such agents, or reverse resistance of fungi to such agents.

5 In addition, the invention provides a method of killing or inhibiting growth of fungi comprising contacting the fungi with a Domain III derived peptide. This method can be practiced *in vivo* or in a variety of *in vitro* uses such as to decontaminate fluids and surfaces and to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints and indwelling invasive devices.

10 A further aspect of the invention involves use of a Domain III derived peptide for the manufacture of a medicament for treatment of fungal infection. The medicament may include, in addition to a Domain III derived peptide, other chemotherapeutic agents such as anti-fungal agents.

15 Numerous additional aspects and advantages of the invention will become apparent to those skilled in the art upon considering the following detailed description of the invention, which describes the presently preferred embodiments thereof.

## 20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 provides results of broth assay tests of the activity of various peptides against *C. albicans*.

25 Figures 2A and 2B provide results of radial diffusion assays of the activity of various peptides against *C. albicans* SLU-1 (Fig. 2A) and *C. albicans* SLU-2G (Fig. 2B).

Figure 3 provides results of broth assay tests of the activity of combinations of peptide and amphotericin B against *C. albicans*.

Figures 4, 5, and 6 graphically represent survival data in mice after *C. albicans* challenge and treatment with peptides or buffer control.

Figures 7 graphically represents survival data in cyclosporin-treated mice after *C. albicans* challenge and treatment with peptides or buffer control.

Figure 8 provides results of RAW cell assay tests of the activity of various peptides.

Figure 9 graphically represents survival data in mice after challenge with *E. coli* 0111:B4 LPS and treatment with peptide.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to the surprising discovery that a Domain III derived peptide has fungicidal activity and can be administered to treat subjects suffering from fungal infection. Also provided are methods of treating fungal infections with such peptides. Unexpectedly, Domain III derived peptides were demonstrated to have anti-fungal activities both in *in vitro* killing assays and in *in vivo* models of fungal infection, as measured, for example, by improved survival or reduction of colony-forming units in circulation after fungal challenge. A variety of fungal infections, including infections caused by *Aspergillus*, infections caused by *Cryptococcus*, such as cryptococcal meningitis, and mucocutaneous and systemic candidiasis caused by *Candida* species, may be treated according to the invention. Also, unexpectedly, Domain III derived peptides were demonstrated to have LPS-neutralizing activity both in an *in vitro* assay and an *in vivo* model. This activity provides an additional benefit in the treatment of fungal infections where bacterial LPS from translocation or additional infection is associated with the fungal infection.

As used herein "Domain III derived peptide" includes peptides having an amino acid sequence of BPI protein from about position 142 to about position 169, subsequences thereof and variants of the sequence or subsequence thereof, which possess antifungal activity. Specifically included are those antifungal peptides having six to fourteen amino acids and having the

amino acid sequence of BPI protein from about position 148 to about position 161, subsequences thereof and variants of the sequence or subsequence. Certain preferred peptides have fourteen amino acids and among the preferred variant sequences and subsequences are those having K as an amino acid corresponding to G at position 152. Preferred peptide sequences with fourteen amino acids have a core amino acid sequence selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF or a variant core amino acid sequence having at least 75% homology to said core amino acid sequence and include the peptides of SEQ ID NOS: 4 (XMP.13), 6-19 (XMP.31-44), 21-22 (XMP.82-83), 23-25 (XMP.85-87), 26-27 (XMP.91-92), 28-31 (XMP.94-97), 32-33 (XMP.100-101), 34 (XMP.104), 35-40 (XMP.106-111), 41 (XMP.113), 42 (XMP.116), 43-55 (XMP.123-135), 57-58 (XMP.138-139), 59-61 (XMP.142-144), 62 (XMP.146), 66-78 (XMP.222-234), 80-88 (XMP.236-244), 89-109 (XMP.249-269) and 116 (XMP.283). This group of antifungal 14 mer peptides includes variant sequence peptides wherein at least one BPI sequence residue has been replaced by a D-isomer amino acid. See, *e.g.*, SEQ ID NOS: 46(XMP.126), 48 (XMP.128), 86-87 (XMP.242-243) and 92-93 (XMP.252-253). Variants involving BPI sequence replacements by atypical amino acids such as  $\beta$ (1-naphthyl)A,  $\beta$ (2-naphthyl)A, para-amino F, cyclohexyl A,  $\alpha$ - and  $\gamma$ -aminobutyric acids,  $\alpha$  methyl A and N-methyl G, V and L are also included within this group.

Among the presently preferred Domain III derived antifungal peptides of the invention having from seven to twelve amino acids comprising:

25 (a) a core sequence of amino acids selected from the group consisting of LIQL, IQLF, WLIQL, LIQLF and WLIQLF; and (b) one or more cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. A subset of peptides have from seven to nine amino acids

30 comprising: (a) a core sequence of amino acids selected from the group

consisting of LIQL and IQLF; and (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Another subset of peptides has from eight to ten amino acids comprising: (a)

5 a core sequence of amino acids selected from the group consisting of LIQLF and WLIQLF; and (b) at least two cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Still another subset of peptides has nine to twelve amino acids comprising: (a) a core sequence of

10 amino acids selected from the group consisting of WLIQLF; and (b) at least three cationic amino acids selected from the group consisting of K, R, H, ornithine and diaminobutyric acid at the amino and/or carboxy terminal portion of the core sequence. Illustrating these subsets are the peptides of SEQ ID NOS: 118-137 (XMP.285-304), 140-144 (XMP.307-311), 155-160

15 (XMP.322-327), 166-170 (XMP.335-339), 174-177 (XMP.343-346), 179-184 (XMP.348-353), 186 (XMP.355), 188-190 (XMP.357-359).

It will be apparent from consideration of the structures of the above-described peptides that the Domain III sequence of BPI amino acids from 148 to 161 includes the core sequence(s) noted above as well as multiple

20 cationic residues (K and H) flanking the core. This motif is carried forward in the structures of subsequences of the 148 to 161 sequence providing antifungal peptides of the invention and also preserved in antifungal variants of the 148 to 161 sequence and subsequences thereof. Note, for example that when the G residue normally in the BPI sequence at position 152 is replaced

25 by K, this replacement serves to provide a cationic residue immediately adjacent to the predominantly hydrophobic core residues. Sequence and subsequence variants providing antifungal peptides according to the invention thus include those peptides wherein one or more existing non-cationic residues ordinarily flanking the core sequence(s) are replaced by cationic residues.

Within the core sequence(s), the neutral aliphatic residues L and I are each replaceable by neutral aliphatic residues G, A, V, I and L. Likewise, the aromatic residues W (BPI position 153) and F (BPI position 158) are replaceable by a different aromatic amino acid residues or by neutral aliphatic residues G, A, V, I and L. Moreover, the core sequence Q (BPI residue 156) is replaceable preferably by a neutral hydrophilic amino acid T, S and N. As noted above, where variations are introduced into core subsequence(s), it is preferable that the variant core sequence(s) retain 75% homology to the sequences occurring in BPI.

Antifungal Domain III peptides of the invention have one or more D-isomer amino acids, as illustrated by the peptides of SEQ ID NOS: 164 (XMP.333), 165 (XMP.334), 173 (XMP.342), 194 (XMP.363) and 196 (XMP.365) and have the core sequence amino acids comprise D-isomer amino acids in reverse sequence order as illustrated by peptides having the amino acid sequence set out in SEQ ID NOS: 163 (XMP.332) and 198 (XMP.367). The antifungal peptides can have an acetylated amino terminal amino acid residue as illustrated by the peptides of SEQ ID NOS: 162 (XMP.331), 185 (XMP.354), 187 (XMP.356), 195 (XMP.364), 199 (XMP.368) and 204 (XMP.373). Cyclic antifungal peptides as illustrated by SEQ ID NOS: 191-193 (XMP.360-362) are also within the scope of the invention.

Additional Domain III antifungal peptides of the invention include antifungal peptides SEQ ID NOS: 1 (XMP.5), 2-4 (XMP.11-13), 5 (XMP.29), 20 (XMP.55), 56 (XMP.137), 79 (XMP.235), 111-115 (XMP.271-275), 117 (XMP.284), 132 (XMP.299), 138-139 (XMP.305-306), 145-154 (XMP.312-321), 200-203 (XMP.369-372), 171-172 (XMP.340-341) and BPI residues 145-159 and 149-163 of SEQ ID NO:206.

Pharmaceutical compositions of the invention comprise a Domain III derived peptide and a pharmaceutically acceptable diluent, adjuvant or carrier and are administered topically, intravenously, orally or as an aerosol.

*In vitro* methods of the invention permit killing or inhibiting replication of fungi through contacting the fungi with an antifungal peptide or pharmaceutical composition containing the same. Fungal infection treatment methods of the invention comprise administering to a subject suffering from a fungal infection a therapeutically effective amount of a Domain III antifungal peptide and such treatment methods are applicable to infections by fungal infection involves a fungal species selected from the group consisting of *Candida* (especially, *C. albicans*, *C. glabrata*, *C. krusei*, *C. lusitaniae*, *C. parapsilosis* and *C. tropicalis*), *Aspergillus* and *Cryptococcus* species.

As described in detail medicaments/pharmaceutical compositions developed according to the invention can include other antifungal agents including non-peptide agents or can be used in combinative therapeutic methods with other such agents.

Peptides derived from or based on BPI produced by recombinant or synthetic means (BPI-derived peptides) have been described in co-owned and copending PCT Application No. US94/10427 filed September 15, 1994, which corresponds to U.S. Patent Application Serial No. 08/306,473, filed September 15, 1994, and PCT Application No. US94/02465 filed March 11, 1994, which corresponds to U.S. Patent Application Serial No. 08/209,762, filed March 11, 1994, which is a continuation-in-part of U.S. Patent Application Serial No. 08/183,222, filed January 14, 1994, which is a continuation-in-part of U.S. Patent Application Ser. No. 08/093,202 filed July 15, 1993 (for which the corresponding international application is PCT Application No. US94/02401 filed March 11, 1994), which is a continuation-in-part of U.S. Patent Application Ser. No. 08/030,644 filed March 12, 1993 (disclosing, *inter alia*, overlapping 15-mer peptides having BPI residues 145-159 and 149-163 of SEQ ID NO. 206), the disclosures of all of which are incorporated herein by reference. BPI-derived peptides having an amino acid sequence of BPI protein from about position 142 to about position 169, subsequences thereof and variants of the sequence or subsequence thereof,

which possess a BPI anti-fungal biological activity, were disclosed in co-owned and co-pending U.S. priority application Serial No. 08/372,105 filed January 13, 1995, the disclosure of which is incorporated herein by reference.

5 The Domain III derived peptide may be administered systemically or topically. Systemic routes of administration include oral, intravenous, intramuscular or subcutaneous injection (including into depots for long-term release), intraocular or retrobulbar, intrathecal, intraperitoneal (*e.g.* by intraperitoneal lavage), transpulmonary using aerosolized or nebulized drug, or transdermal. Topical routes include administration in the form of  
10 salves, ophthalmic drops, ear drops, or irrigation fluids (for, *e.g.*, irrigation of wounds).

The Domain III derived peptide may be administered in conjunction with other anti-fungal agents. Preferred anti-fungal agents for this purpose are amphotericin B and fluconazole. Concurrent administration of  
15 Domain III derived peptide with anti-fungal agents is expected to improve the therapeutic effectiveness of the anti-fungal agents. This may occur through reducing the concentration of anti-fungal agent required to eradicate or inhibit fungal growth, *e.g.*, replication. Because the use of some agents is limited by their systemic toxicity or prohibitive cost, lowering the concentration of  
20 anti-fungal agent required for therapeutic effectiveness reduces toxicity and/or cost of treatment, and thus allows wider use of the agent. Concurrent administration of Domain III derived peptide and another anti-fungal agent may produce a more rapid or complete fungicidal/fungistatic effect than could be achieved with either agent alone. Domain III derived peptide  
25 administration may reverse the resistance of fungi to anti-fungal agents. Domain III derived peptide administration may also convert a fungistatic agent into a fungicidal agent.

An advantage provided by the present invention is the ability to treat fungal infections, particularly *Candida* infections, that are presently  
30 considered incurable. Another advantage is the ability to treat fungi that have



acquired resistance to known anti-fungal agents. A further advantage of concurrent administration of Domain III derived peptide with an anti-fungal agent having undesirable side effects, *e.g.*, amphotericin B, is the ability to reduce the amount of anti-fungal agent needed for effective therapy. The present invention may also provide quality of life benefits due to, *e.g.*, decreased duration of therapy, reduced stay in intensive care units or reduced stay overall in the hospital, with the concomitant reduced risk of serious nosocomial (hospital-acquired) infections.

"Concurrent administration" as used herein includes administration of the agents together, simultaneously or before or after each other. The Domain III derived peptide and anti-fungal agents may be administered by different routes. For example, the Domain III derived peptide may be administered intravenously while the anti-fungal agents are administered intramuscularly, intravenously, subcutaneously, orally or intraperitoneally. Alternatively, the Domain III derived peptide may be administered intraperitoneally while the anti-fungal agents are administered intraperitoneally or intravenously, or the Domain III derived peptide may be administered in an aerosolized or nebulized form while the anti-fungal agents are administered, *e.g.*, intravenously. The Domain III derived peptide and anti-fungal agents may be both administered intravenously. The Domain III derived peptide and anti-fungal agents may be given sequentially in the same intravenous line, after an intermediate flush, or may be given in different intravenous lines. The Domain III derived peptide and anti-fungal agents may be administered simultaneously or sequentially, as long as they are given in a manner sufficient to allow both agents to achieve effective concentrations at the site of infection.

Concurrent administration of Domain III derived peptide and another anti-fungal agent is expected to provide more effective treatment of fungal infections. Concurrent administration of the two agents may provide greater therapeutic effects *in vivo* than either agent provides when

administered singly. For example, concurrent administration may permit a reduction in the dosage of one or both agents with achievement of a similar therapeutic effect. Alternatively, the concurrent administration may produce a more rapid or complete fungicidal/fungistatic effect than could be achieved with either agent alone.

Therapeutic effectiveness is based on a successful clinical outcome, and does not require that the anti-fungal agent or agents kill 100% of the organisms involved in the infection. Success depends on achieving a level of anti-fungal activity at the site of infection that is sufficient to inhibit the fungi in a manner that tips the balance in favor of the host. When host defenses are maximally effective, the anti-fungal effect required may be minimal. Reducing organism load by even one log (a factor of 10) may permit the host's own defenses to control the infection. In addition, augmenting an early fungicidal/fungistatic effect can be more important than long-term fungicidal/fungistatic effect. These early events are a significant and critical part of therapeutic success, because they allow time for host defense mechanisms to activate.

A Domain III derived peptide may interact with a variety of host defense elements present in whole blood or serum, including complement, p15 and LBP, and other cells and components of the immune system. Such interactions may result in potentiation of the activities of the peptide. Because of these interactions, Domain III derived peptides can be expected to exert even greater activity *in vivo* than *in vitro*. Thus, while *in vitro* tests are predictive of *in vivo* utility, absence of activity *in vitro* does not necessarily indicate absence of activity *in vivo*. For example, BPI has been observed to display a greater bactericidal effect on gram-negative bacteria in whole blood or plasma assays than in assays using conventional media. [Weiss et al., *J. Clin. Invest.* 90:1122-1130 (1992)]. This may be because conventional *in vitro* systems lack the blood elements that facilitate or potentiate BPI's function *in vivo*, or because conventional media contain

higher than physiological concentrations of magnesium and calcium, which are typically inhibitors of the activity of BPI protein products. Furthermore, in the host, Domain III derived peptides are available to neutralize translocation of gram-negative bacteria and concomitant release of endotoxin, a further clinical benefit not seen in or predicted by *in vitro* tests of anti-fungal activity.

It is also contemplated that the Domain III derived peptides be administered with other products that potentiate the activity of the peptide, including the anti-fungal activity of the peptides. For example, serum complement potentiates the gram-negative bactericidal activity of BPI protein products; the combination of BPI protein product and serum complement provides synergistic bactericidal/growth inhibitory effects. See, *e.g.*, Ooi *et al. J. Biol. Chem.*, 265: 15956 (1990) and Levy *et al. J. Biol. Chem.*, 268: 6038-6083 (1993) which address naturally-occurring 15 kD proteins potentiating BPI antibacterial activity. See also co-owned, co-pending PCT Application No. US94/07834 filed July 13, 1994, which corresponds to U.S. Patent Application Serial No. 08/274,303 filed July 11, 1994 as a continuation-in-part of U.S. Patent Application Serial No. 08/093,201 filed July 14, 1993. These applications, which are all incorporated herein by reference, describe methods for potentiating gram-negative bactericidal activity of BPI protein products by administering lipopolysaccharide binding protein (LBP) and LBP protein products. LBP protein derivatives and derivative hybrids which lack CD-14 immunostimulatory properties are described in PCT Application No. US94/06931 filed June 17, 1994, which corresponds to co-owned, co-pending U.S. Patent Application Serial No. 08/261,660, filed June 17, 1994 as a continuation-in-part of U.S. Patent Application Serial No. 08/079,510, filed June 17, 1993, the disclosures of all of which are hereby incorporated by reference. It has also been observed that poloxamer surfactants enhance the anti-bacterial activity of BPI protein products, as described in Lambert, U.S. Application No. 08/372, 104 filed January 13,

1995; poloxamer surfactants may also enhance the activity of anti-fungal agents.

Without being bound by a theory of the invention, it is believed that Domain III derived peptides may have several modes of action. The peptide, through its heparin-binding ability, may interfere with the binding of fungi to the extracellular matrix. For example, heparin-like surface molecules of *Candida* are believed to mediate adhesion of the yeast to extracellular matrix and host tissues. The peptide may also act directly on the cytoplasmic membrane of fungi. In addition, the peptide may bind to fungal cell wall mannoproteins that are structurally similar to the LPS of gram-negative organisms or that are responsible for adherence to target host tissues, thus interfering with fungal interaction with host tissues. Binding to fungal mannans may also promote access of the peptide to the inner cytoplasmic membrane. In addition, because fungal infection may cause stress-induced translocation of bowel flora and/or LPS, the peptide may also act beneficially by killing gram-negative bacteria and neutralizing LPS. Finally, the antifungal activity of Domain III peptides according to the invention may result from unique structural features. For example, a six amino acid sequence within Domain III (WLIQLF) and the included five and four amino acid sequences (LIQL, IQLF, WLIQL and LIQLF) are composed of hydrophobic amino acids with the exception of glutamine (Q) that is a neutral hydrophilic amino acid. This hydrophobic stretch is bounded by highly cationic (polar) lysines on the N- and C-termini. This motif is reminiscent of leader/signal peptides as well as transmembrane segments of membrane proteins. Aliphatic amino acids such as I, L, V, M, A, have a high propensity to form transmembrane  $\alpha$ -helical structures within the hydrophobic membrane environment when found in sequences of 12-15 nonpolar amino acids due to their ability to form backbone hydrogen bonds. Aromatic hydrophobic amino acids such as W and F can also incorporate into a membrane  $\alpha$ -helix. The neutral, hydrophilic glutamine in the middle of a

Domain III hydrophobic stretch may participate in hydrogen bonding with other fungal membrane components such as ergosterol and thus play an important role in the fungicidal activity. A short 10 amino acid peptide (*e.g.*, XMP.293) is not expected to be long enough to span a lipid bilayer and probably has a much different mechanism of action than a membrane disrupting, amphipathic type of cationic antimicrobial peptide. The short motif of six to twelve amino acid peptides with a core of neutral amino acids bounded by cationic amino acids is not long enough to span a fungal lipid bilayer and thus may be allowed to traverse the membrane bilayer more efficiently than longer peptides. If transported inside the cell, the cationic/neutral/cationic molecules may inhibit the function of endogenous polyamines (spermidine, spermine, putrescine) by either competitive inhibition of the polyamine regulation of cell wall carbohydrate synthesis and/or by feedback inhibition of polyamine synthesis.

In addition, the invention provides a method of killing or inhibiting growth of fungi comprising contacting the fungi with a Domain III derived peptide. This method can be practiced *in vivo* or in a variety of *in vitro* uses such as use in food preparations or to decontaminate fluids and surfaces or to sterilize surgical and other medical equipment and implantable devices, including prosthetic joints. These methods can also be used for *in situ* sterilization of indwelling invasive devices such as intravenous lines and catheters, which are often foci of infection.

A further aspect of the invention involves use of a Domain III derived peptide for the manufacture of a medicament for treatment of fungal infection. The medicament may include, in addition to a BPI protein product, other chemotherapeutic agents such as anti-fungal agents. The medicament can optionally comprise a pharmaceutically acceptable diluent, adjuvant or carrier.

The administration of antifungal peptides is suitably accomplished with a pharmaceutical composition comprising a peptide and a

pharmaceutically acceptable diluent, adjuvant, or carrier. The peptide may be administered without or in conjunction with known surfactants, other chemotherapeutic agents or additional known anti-fungal agents.

Other aspects and advantages of the present invention will be understood upon consideration of the following illustrative examples wherein Example 1 addresses peptide preparation and purification; Example 2 addresses *in vitro* anti-fungal testing of peptides; Example 3 addresses additional *in vitro* and *in vivo* testing of the anti-fungal effect of peptides on a variety of fungal species, including *Candida* strains and antibiotic resistant strains; Example 4 addresses the *in vivo* effect of peptides on survival of mice challenged with *Candida*; Example 5 addresses the serum stability of peptides; Example 6 addresses the design and assay of anti-fungal peptides for structural motif and minimum functional sequence analysis; Example 7 addresses LPS neutralization activities of anti-fungal peptides; and Example 8 addresses peptide formulations.

20

25

30

## Example 1

## PEPTIDE PREPARATION AND PURIFICATION

This example addresses the preparation and purification of Domain III derived peptides.

5           Peptides may be prepared according to a variety of synthetic procedures. Some peptides (*e.g.*, XMP.5) were prepared by solid phase peptide synthesis as described in parent U.S. Patent Application Serial Nos. 08/209,762 and 08/183,222 according to the methods of Merrifield, *J. Am Chem. Soc.* 85: 2149 (1963) and Merrifield *et al. Anal. Chem.*, 38: 1905-  
10   1914 (1966) using an Applied Biosystems, Inc. Model 432 peptide synthesizer.

          Alternatively, peptides were synthesized on a larger scale using solid phase peptide synthesis on an Advanced Chemtech (ACT-Model 357 MPS) synthesizer utilizing a 1-Fluorenylmethyl-oxycarbonyl (Fmoc) protection  
15   strategy with a double coupling procedure employing N,N-diisopropylcarbodiimide (DIC)/1-hydroxybenzotriazole (HOBt) and 2-(1-H-benzotriazol-1-yl)-1,1,3,3,-tetramethyluronium hexa-fluorophosphate (HBTU)/HOBt/diisopropylethylamine (DIEA). The solid support used was a polystyrene resin with 1% divinylbenzene (DVB) cross-linking and an 4-  
20   (2',4'-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy (Fmoc-Rink amide) linker with a substitution rate of 0.44 mmoles/gram. The scale used was between 0.1 grams and 5 grams of starting resin.

          Dimethylformamide (DMF) was the primary solvent with a 50/50 solution of piperidine/DMF used for Fmoc deprotection in three  
25   consecutive treatments of 1, 5, and 10 minutes, respectively. A double coupling procedure was used in each cycle with a 4:1 amino acid to peptide ratio used in each coupling. The amino acids were dissolved in a 0.5M HOBt solution in N-methylpyrrolidinone (NMP) at a concentration also of 0.5M. For the first coupling, an equimolar (to amino acid) amount of a 0.5M  
30   solution of diisopropylcarbodiimide (DIPCDI) in NMP was used and allowed



to react for 45 minutes. The second coupling utilized an equimolar (to amino acid) volume of a 0.5M HBTU solution in DMF with an equal volume of a 1M DIEA solution in NMP (2:1, DIEA:amino acid) for a period of 30 minutes.

5                   Upon completion of the synthesis, the resin was treated with MeOH, dried under vacuum, and then cleaved using a cocktail composed of trifluoroacetic acid (TFA) : thioanisole : ethanedithiol (EDT) : water, at a ratio of 36:2:1:1 (volume was dependent on the amount of resin) for a minimum of 2 hours with an additional 30 minutes added for each arginine  
10 (but not exceeding 3 hours) with the first 15 minutes occurring in a wet ice bath. The solutions were then dissolved in a 10% TFA in water solution, washed 3 times with methyl t-butyl ether (MTBE) and lyophilized.

                  The amino termini of selected peptides were acetylated after synthesis on solid phase using an N-terminal Fmoc protection strategy as  
15 described above. Subsequent to Fmoc removal with piperidine and prior to peptide cleavage with TFA, the peptide on the resin was derivatized with a 10-fold molar excess of acetic anhydride with a 2-fold molar excess of diisopropylethylamine in dimethylformamide for one hour. The peptide was then cleaved from the resin with the TFA cleavage cocktail as described above  
20 and purified as described below. N-terminal acetylation of the purified peptide was verified by mass spectrometry.

                  For purity analysis of each newly synthesized peptide, dilute solutions of crude lyophilized peptides were prepared and analyzed on a Michrom Ultrafast Microprotein Analyzer equipped with a 150 mm X 1 mm,  
25 5  $\mu$  particle, 300 Å pore C-8 Zorbax column. The column oven was set to 40°C, the flow rate was 100  $\mu$ L/minute, and injection volumes were typically 5-10  $\mu$ L. HPLC was performed using 5% acetonitrile/0.1% TFA in water as mobile phase A, and 80% acetonitrile/0.065% TFA as mobile phase B. The eluate was monitored spectrophotometrically at 214 nm. Percent purity is  
30 calculated from the peak area of the individual peptides (see Table 1).

Selected peptides were purified by high performance liquid chromatography (HPLC), using a Waters Prep LC 2000 Preparative Chromatography System (Water Corp., Milford, MA) equipped with a Delta Pak C-18, 15  $\mu$ m, 300 Å cartridge column consisting of a 40 X 10 mm guard cartridge and a 40 X 100 mm Prep Pak cartridge. The column was equilibrated in 25 % buffer B, where A=5 % acetonitrile/0.1 % trifluoroacetic acid and B=80 % acetonitrile/0.065 % trifluoroacetic acid. Peptides were dissolved to ~20 mg/mL in buffer A and 200-800 mg were applied to the column through the LC pump operating at a flow rate of 8-17 mL/min. Bound material was eluted with a gradient of 25-35 % buffer B/30 min applied at 8-17 mL/min. (Some peptides were purified with a gradient of 23-33 %B/30 min.) The eluate was monitored at 220 and/or 280 and 300 nm with a Waters 490E Programmable Multiwavelength Detector. Fractions were collected and assayed for the peptide of interest on an Ultrafast Micoprotein Analyzer (Michrom BioResources, Inc., Pleasanton, CA) equipped with a Zorbax C-8, 150 X 1 mm, 5  $\mu$ m, 300 Å maintained at 40°C. Fractions containing the peptide of interest at  $\geq 95$  % purity were pooled and lyophilized to dryness. The purity of the recovered material was determined with analytical reverse-phase HPLC.

20

### Example 2

#### IN VITRO ANTI-FUNGAL EFFECTS

This example addresses *in vitro* screening of Domain III derived peptides for anti-fungal activity in a broth assay and/or in a radial diffusion assay.

25

Table 1 below sets out peptides derived from or based on Domain III BPI sequences. Such peptides may be identified by peptide number with a prefix XMP or BPI (*e.g.*, XMP.1 or BPI.1, XMP.2 or BPI.2, etc.). Table 1 also sets out the SEQ ID NO: of each peptide, the amino acid sequence based on reference to position within BPI and the designation of amino acid

30

substitutions and additions. Also set out in Table 1 are HPLC estimates of purity of the peptides. The HPLC purity analysis was performed as described in Example 1.

In each broth assay screening procedure, a colony of *C. albicans* designated CA-1, Strain SLU-1 that was received from the laboratories of G. Matuschak and A. Lechner, St. Louis University Hospital, St. Louis, MO, where the strain was maintained, was inoculated into a tube containing 5 mL Sabouraud Dextrose broth (2% dextrose, 1% neopeptone) and incubated overnight at 37°C with shaking. The overnight culture was diluted 1:50 into 5 mL of fresh broth and incubated for 3 hours at 37°C. Organisms were pelleted by centrifugation in a Beckman J-6M centrifuge for 5 minutes at 3000 rpm (1500 x g) and the pellets were resuspended in 5 mL phosphate buffered saline (PBS) and the optical density at 570 nm was determined. On the basis of the determination that one OD unit equals  $3 \times 10^7$  colony forming units/mL, yeast cells were diluted to  $2 \times 10^6$  cells/mL in Sabouraud Dextrose broth.

Domain III peptides derived from or based on BPI to be screened were originally constituted in Dulbecco's-PBS, were diluted to 100  $\mu\text{g/mL}$  in broth and were serially diluted 2-fold into wells of a 96 well sterile, flat bottom, non-pyrogenic tissue culture plate (Costar, Cambridge, MA). All assays were performed in triplicate.  $2 \times 10^5$  organisms were added at 100  $\mu\text{l}$  per well; final volume was 200  $\mu\text{L/well}$ ; the plate was incubated on a shaker at 37°C for 18 hours; and the optical densities for each well were read at 590 nm. Figure 1 hereto graphically illustrates the dose response curves for five peptides (XMP.13, XMP.138, XMP.139, XMP.142 and XMP.143). All illustrated peptides reduced optical density of the cultures to below 0.1 at doses of less than about 50  $\mu\text{g/mL}$ , with XMP.138 displaying the best results of the illustrated peptides at low dosages. The broth assay data may be set out in terms of minimum inhibitory concentration (MIC), *i.e.* the lowest concentration required to reduce the optical density at 590 nm to below 0.1.

The MIC ( $\mu\text{g/mL}$ ) of each of the five peptides listed above in Figure 1 is 12.5, 3.13, 6.25, 12.5 and 25.0, respectively.

In the radial diffusion assay procedures, the CA-1 cultures and peptide solutions were prepared as in the broth assay procedure described above. Ten mL of molten underlayer agarose comprising 3% Sabouraud Dextrose broth, 1% agarose (Pharmacia, Piscataway, NJ), 0.02% Tween 20, and 10 mM sodium phosphate at pH 7.4, was added to polystyrene tubes and maintained in a 56°C water bath until the addition of yeast. Tubes were cooled to approximately 45°C, yeast were added to give a final concentration of  $1 \times 10^6$  CFU/mL, and the tubes were mixed again by inverting. The contents were poured into level square petri dishes and distributed evenly. The agarose solidified in less than 30 seconds and had a uniform thickness of about 1 mm. A series of wells were punched into the hardened agarose using a sterile 3 mm punch attached to a vacuum apparatus.

Peptides to be assayed were 2-fold serially diluted in Dulbecco's PBS (D-PBS) starting from a concentration of approximately 1 mg/mL. Five  $\mu\text{L}$  of each dilution were added to each well and the plates were incubated at 37°C for 3 hours. An overlayer of 10 mL of molten agarose comprising 6% Sabouraud Dextrose broth, 1% agarose, and 10 mM sodium phosphate, pH 7.4, (at approximately 45°C) was then added and plates were incubated overnight at 37°C. Following this overnight incubation, a dilute Coomassie solution was poured into the plates and allowed to stain for 24 hours.

Clear zones of growth inhibition around each well were measured with calipers. The actual area of growth inhibition ( $\text{mm}^2$ ) was calculated by subtracting the area of the well. Table 1 below sets out the results of the radial diffusion assays for tested peptides in terms of the number of picomoles (pmol) of peptide required to establish a 30  $\text{mm}^2$  area of growth inhibition calculated by PROBIT analysis (*e.g.*, calculated from regression of the linear portion of log-concentration dose-response curve, log pmol/well vs. net area of inhibition).

TABLE 1

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.5 (1)	142-163	18	>2151
XMP.11 (2)	148-151, 153-161	76	645
XMP.12 (3)	141-169	26	>2099
XMP.13 (4)	148-161	69	541
XMP.13P <sup>f</sup> (4)	148-161	98	222
XMP.29 (5)	(148-161) x 2	26	>1469
XMP.31 (6)	148-161, A @ 148 (K)	68	426
XMP.32 (7)	148-161, A @ 149 (S)	70	294
XMP.33 (8)	148-161, A @ 150 (K)	58	603
XMP.34 (9)	148-161, A @ 151 (V)	51	319
XMP.35 (10)	148-161, A @ 152 (G)	72	442
XMP.36 (11)	148-161, A @ 153 (W)	64	197

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.36 (11)	148-161, A @ 153 (W)	99	231
XMP.37 (12)	148-161, A @ 154 (L)	51	253
XMP.38 (13)	148-161, A @ 155 (I)	70	391
XMP.39 (14)	148-161, A @ 156 (Q)	53	1792
XMP.40 (15)	148-161, A @ 157 (L)	53	253
XMP.41 (16)	148-161, A @ 158 (F)	63	734
XMP.42 (17)	148-161, A @ 159 (H)	59	548
XMP.43 (18)	148-161, A @ 160 (K)	53	785
XMP.44 (19)	148-161, A @ 161 (K)	70	578
XMP.55 (20)	152-172	28	>2666
XMP.82 (21)	148-161, W @ 158 (F)	58	518

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.83 (22)	148-161, $\beta$ (1-naphthyl)-A @ 153 (W)	63	1804
XMP.85 (23)	148-161, L @ 152 (G)	74	>1881
XMP.86 (24)	148-161, L @ 156 (Q)	51	>2048
XMP.87 (25)	148-161, L @ 159 (H)	63	>1536
XMP.91 (26)	148-161, F @ 156 (Q)	31	>3844
XMP.92 (27)	148-161, K @ 156 (Q)	50	299
XMP.94 (28)	148-161, F @ 159 (H)	59	>923
XMP.95 (29)	148-161, F @ 152 (G)	57	>1398
XMP.96 (30)	148-161, F @ 161 (K)	60	1856
XMP.97 (31)	148-161, K @ 152 (G)	67	213



TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.97P' (31)	148-161, K @ 152 (G)	98	303.5
XMP.100 (32)	148-161, K @ 152 (G) & 156 (Q)	61	462
XMP.101 (33)	(148-161) x 2[K @ 152(G) & 156(Q), F @ 159(H) & 161(K)]	16	> 1040
XMP.104 (34)	148 - 161, S @ 156 (Q)	34	> 5569
XMP.106 (35)	148 - 161, T @ 156 (Q)	26	1032
XMP.107 (36)	148 - 161, W @ 159 (H)	55	> 2796
XMP.108 (37)	148 - 161, W @ 161 (K)	50	> 3219
XMP.109 (38)	148-161, $\beta$ (1-naphthyl)-A @ 158 (F)	41	> 2839
XMP.110 (39)	148-161, $\beta$ (1-naphthyl)-A @ 159 (H)	56	> 2922

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.111 (40)	148-161, $\beta$ (1-naphthyl)-A @ 161 (K)	73	>2809
XMP.113 (41)	148 - 161, F @ 157 (L)	46	947
XMP.116 (42)	148-161, K @ 152 (G), $\beta$ (1-naphthyl)-A @ 153 (W)	72	670
XMP.123 (43)	148-161, p-Amino-F @ 156 (Q)	64	1721
XMP.124 (44)	148-161, K @ 152(G), W @ 158 (F)	67	351
XMP.125 (45)	148-161, Y @ 156 (Q)	54	>3150
XMP.126 (46)	148-161, W <sub>b</sub> @ 153 (W)	54	1404
XMP.127 (47)	148-161, F @ 153 (W)	63	226
XMP.127P <sup>f</sup> (47)	148-161, F @ 153 (W)	94	935
XMP.128 (48)	148-161 F <sub>b</sub> @ 153 (W)	51	1179

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.129 (49)	148-161, $\beta$ (1-naphthyl)A <sub>D</sub> @ 153 (W)	28	2117
XMP.130 (50)	148-161, $\beta$ (2-naphthyl)A @ 153 (W)	80	1159
XMP.131 (51)	148-161, $\beta$ (2-naphthyl)A <sub>D</sub> @ 153 (W)	60	2493
XMP.132 (52)	148 - 161, PYR @ 153 (W)	50	353
XMP.133 (53)	148-161, p-Amino-F @ 153 (W)	47	284
XMP.134 (54)	148-161, p-Amino-F @ 152 (G)	68	1255
XMP.135 (55)	148-161, K @ 153 (W)	70	428
XMP.137 (56)	C-148-161-C	28	>2286
XMP.138 (57)	148-161, K @ 152 (G), F @ 153 (W)	61	257
XMP.139 (58)	148-161, Y @ 153 (W)	60	323

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone*
XMP.142 (59)	148-161, W @ 157 (L)	57	1244
XMP.143 (60)	148-161, $\beta$ (1-naphthyl)-A @ 157 (L)	65	>2839
XMP.144 (61)	148-161, Cyclohexyl-A @ 153 (W)	60	695
XMP.146 (62)	148-161, $\beta$ (1-naphthyl)-A @ 159 (H) & 161 (K)	53	b
XMP.148 (63)	148-161, $\beta$ (1-naphthyl)-A @ 153 (W) & 159 (H)	62	>2805
XMP.161 (64)	148-161, K @ 152 (G) & A @ 153 (W)	75	>2999
XMP.166 (65)	148-161, V @ 153 (W)	68	171
XMP.222 (66)	148-161 $\beta$ (1-naphthyl)-A @ 153 (W) & 161 (K)	57	>2,610

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.223 (67)	148-161, $\beta$ (1-naphthyl)-A @ 153 (W) & 157 (L)	39	b
XMP.224 (68)	148-161, $\beta$ (1-naphthyl)-A @ 153, p-amino- F @ 156 (Q)	55	> 2,443
XMP.225 (69)	148-161, p-amino-F @ 152, $\beta$ (1-naphthyl)- A @ 153 (W)	77	> 2,506
XMP.226 (70)	148-161, $\beta$ (1-naphthyl)-A @ 153, W @ 158 (F)	50	> 2,597
XMP.227 (71)	148-161, $\beta$ (1-naphthyl)-A @ 157 (L) & 161 (K)	54	> 2,365
XMP.228 (72)	148-161, p-amino-F @ 156 (Q), $\beta$ (1- naphthyl)-A @ 161 (K)	43	b
XMP.229 (73)	148-161, p-amino-F @ 152 (G), $\beta$ (1- naphthyl)-A @ 161 (K)	81	b

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.230 (74)	148-161, W @ 158 (F), $\beta$ (1-naphthyl)-A @ 161 (K)	51	>2,386
XMP.231 (75)	148-161, $\beta$ (1-naphthyl)-A @ 157 (L) & 159 (H)	44	b
XMP.232 (76)	148-161, p-amino-F @ 156 (Q), $\beta$ (1- naphthyl)-A @ 159 (H)	28	b
XMP.233 (77)	148-161, p-amino-F @ 152 (G), $\beta$ (1- naphthyl)-A @ 159 (H)	53	b
XMP.234 (78)	148-161, W @ 158 (F), $\beta$ (1-naphthyl)-A @ 159 (H)	26	b
XMP.235 (79)	148-161, p-amino-F @ 156 (Q), $\beta$ (1- naphthyl)-A @ 157 (L)	30	b
XMP.236 (80)	148-161, p-amino-F @ 152 (G), $\beta$ (1- naphthyl)-A @ 157 (L)	73	>2,631

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.237 (81)	148-161, $\beta$ (1-naphthyl)-A @ 157 (L), W @ 158 (F)	34	> 2,777
XMP.238 (82)	148-161, p-amino-F @ 152 (G) & 156 (Q)	66	2,702
XMP.239 (83)	148-161, p-amino-F @ 156 (Q), W @ 158 (F)	30	> 2,802
XMP.240 (84)	148-161, p-amino-F @ 152 (G), W @ 158 (F)	55	> 2,802
XMP.241 (85)	148-161, L @ 156(Q), W @ 158 (F)	55	> 2,161
XMP.242 (86)	148-161, $\beta$ (2-naphthyl)A <sub>b</sub> @ 153 (W), L @ 156 (Q)	52	359
XMP.243 (87)	148-161, $\beta$ (2-naphthyl)A <sub>b</sub> @ 153 (W), W @ 158 (F)	Mixture	716



TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.244 (88)	148-161, $\beta$ (2-naphthyl)A <sub>b</sub> @ 153 (W), L @ 156 (Q), W @ 158 (F)	43	859
XMP.249 (89)	148-161, G @ 153 (W)	46	1,242
XMP.250 (90)	148-161, L @ 153 (W)	33	536
XMP.251 (91)	148-161, I @ 153 (W)	44	1,289
XMP.252 (92)	148-161, A <sub>b</sub> @ 153 (W)	52	1,613
XMP.253 (93)	148-161, V <sub>b</sub> @ 153 (W)	51	1,108
XMP.254 (94)	148-161, $\beta$ -A @ 153 (W)	68	1,040
XMP.255 (95)	148-161, $\alpha$ -Aminobutyric Acid @ 153 (W)	44	392
XMP.256 (96)	148-161, $\gamma$ -Aminobutyric Acid @ 153(W)	38	b
XMP.257 (97)	148-161, $\alpha$ -Methyl-A @ 153 (W)	44	1,321

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.258 (98)	148-161, t-Butyl-G @ 153 (W)	62	880
XMP.259 (99)	148-161, N-Methyl-G @ 153 (W)	88	2,117
XMP.260 (100)	148-161, N-Methyl-V @ 153 (W)	75	742
XMP.261 (101)	148-161, N-Methyl-L @ 153 (W)	85	867
XMP.262 (102)	148-161, N @ 156 (Q)	68	984
XMP.263 (103)	148-161, E @ 156 (Q)	49	1,197
XMP.264 (104)	148-161, D @ 156 (Q)	60	879
XMP.265 (105)	148-161, R @ 156 (Q)	42	2,996
XMP.266 (106)	148-161, K @ 152(G), V @ 153 (W)	52	984
XMP.267 (107)	148-161, K @ 152 (G), A @ 154 (L)	58	256
XMP.268 (108)	148-161, V @ 153 (W), A @ 154 (L)	48	308

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.269 (109)	148-161, K @ 152 (G), V @ 153 (W), A @ 154 (L)	30	635
XMP.270 (110)	(148-161)+(148-161), L @ 1st 156 (Q)	31	> 722
XMP.271 (111)	(148-161)+(148-161), L @ 2nd 156 (Q)	31	> 1,995
XMP.272 (112)	(148-161)+(148-161), L @ both 156 (Q)	32	> 2,599
XMP.273 (113)	(148-161)+(148-161), F @ 1st 156 (Q)	59	> 2,120
XMP.274 (114)	(148-161)+(148-161), F @ 2nd 156 (Q)	40	> 2,457
XMP.275 (115)	(148-161)+(148-161), F @ both 156 (Q)	34	b
XMP.283 (116)	148-161, K @ 152 (G), F @ 153 (W), K @ 156 (Q)	36	1,336
XMP.284 (117)	149-161, K @ 152 (G)	60	1,460
XMP.284P <sup>f</sup> (117)	149-161, K @ 152 (G)	96	373

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.285 (118)	149-160, K @ 152 (G)	75	> 3,024
XMP.286 (119)	150-161, K @ 152 (G)	61	1,216
XMP.286P' (119)	150-161, K @ 152 (G)	80	253
XMP.287 (120)	149-159, K @ 152 (G)	58	> 3,509
XMP.288 (121)	150-160, K @ 152 (G)	78	> 3,062
XMP.288P' (121)	150-160, K @ 152 (G)	94	279
XMP.289 (122)	151-161, K @ 152 (G)	78	1,542
XMP.289P' (122)	151-161, K @ 152 (G)	94	658
XMP.290 (123)	149-158, K @ 152 (G)	79	> 2,233
XMP.291 (124)	150-159, K @ 152 (G)	55	> 5,039
XMP.292 (125)	151-160, K @ 152 (G)	78	> 4,463
XMP.293 (126)	152-161, K @ 152 (G)	78	1,156

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone*
XMP.293P <sup>f</sup> (126)	152-161, K @ 152 (G)	95	215
XMP.294 (127)	149-157, K @ 152 (G)	63	>4,634
XMP.295 (128)	150-158, K @ 152 (G)	82	>1,977
XMP.295P <sup>f</sup> (128)	150-158, K @ 152 (G)	c	>2,612
XMP.296 (129)	151-159, K @ 152 (G)	64	>5,573
XMP.297 (130)	152-160 K @ 152 (G)	81	1,817
XMP.297P <sup>f</sup> (130)	152-160 K @ 152 (G)	94	564
XMP.298 (131)	153-161	84	2,628
XMP.298P <sup>f</sup> (131)	153-161	95	1,106
XMP.299 (132)	149-156, K @ 152 (G)	68	>8,768
XMP.300 (133)	150-157, K @ 152 (G)	75	1,957
XMP.300P <sup>f</sup> (133)	150-157, K @ 152 (G)	97	993

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.301 (134)	151-158, K @ 152 (G)	41	b
XMP.302 (135)	152-159, K @ 152 (G)	75	>5,497
XMP.302P <sup>f</sup> (135)	152-159, K @ 152 (G)	98	2,070
XMP.303 (136)	153-160	78	>4,694
XMP.303P <sup>f</sup> (136)	153-160	98	1,307
XMP.304 (137)	154-161	84	>8,290
XMP.305 (138)	149-155, K @ 152 (G)	73	>10,228
XMP.306 (139)	150-156, K @ 152 (G)	62	>10,485
XMP.307 (140)	151-157, K @ 152 (G)	67	>8,345
XMP.308 (141)	152-158, K @ 152 (G)	72	b
XMP.309 (142)	153-159	76	b
XMP.310 (143)	154-160	56	>9,475

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.311 (144)	155-161	77	b
XMP.312 (145)	149-154, K @ 152 (G)	76	> 11,120
XMP.313 (146)	150-155, K @ 152 (G)	59	> 11,050
XMP.314 (147)	151-156, K @ 152 (G)	73	> 13,497
XMP.315 (148)	152-157, K @ 152 (G)	84	> 5,069
XMP.315P' (148)	152-157, K @ 152 (G)	94	> 12,853
XMP.316 (149)	153-158	85	b
XMP.317 (150)	154-159	64	b
XMP.318 (151)	155-160	84	b
XMP.319 (152)	156-161	73	b
XMP.320 (153)	153-157	63	> 4,055
XMP.321 (154)	153-157 - K	66	> 5,851



TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.322 (155)	153-157 - K - K	69	3,488
XMP.323 (156)	K - 153 - 157 - K	63	>4,627
XMP.324 (157)	K - 153 - 157 - K - K	67	894
XMP.325 (158)	K - K - 153 - 157	66	4,135
XMP.326 (159)	K - K - 153 - 157 - K	59	2,182
XMP.327 (160)	K - K - 153 - 157 - K - K	62	353
XMP.327P <sup>f</sup> (160)	K - K - 153 - 157 - K - K	94	630
XMP.330 (161)	153-156	95	b
XMP.331 (162)	† K - K - 153 - 157 - K - K	66	b
XMP.331P <sup>f</sup> (162)	† K - K - 153 - 157 - K - K	97	>3,493
XMP.332 (163)	K <sub>D</sub> - K <sub>D</sub> - L <sub>D</sub> - Q <sub>D</sub> - I <sub>D</sub> - L <sub>D</sub> - W <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	64	356
XMP.332P <sup>f</sup> (163)	K <sub>D</sub> - K <sub>D</sub> - L <sub>D</sub> - Q <sub>D</sub> - I <sub>D</sub> - L <sub>D</sub> - W <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	98	338

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.333 (164)	K <sub>D</sub> - K - 153 - 157 - K - K	62	673
XMP.333P <sup>f</sup> (164)	K <sub>D</sub> - K - 153 - 157 - K - K	98	361
XMP.334 (165)	P <sub>D</sub> - K - 153 - 157 - K - K	67	1,449
XMP.334P <sup>f</sup> (165)	P <sub>D</sub> - K - 153 - 157 - K - K	89	1,065
XMP.335 (166)	P - K - 153 - 157 - K - K	61	871
XMP.335P <sup>f</sup> (166)	P - K - 153 - 157 - K - K	98	1,353
XMP.336 (167)	R - R - 153 - 157 - R - R	22	>7,332
XMP.337 (168)	H - H - 153 - 157 - H - H	70	b
XMP.337P <sup>f</sup> (168)	H - H - 153 - 157 - H - H	94	>3,350
XMP.338 (169)	ORN - ORN - 153 - 157 - ORN - ORN	74	1,194
XMP.338P <sup>f</sup> (169)	ORN - ORN - 153 - 157 - ORN - ORN	96	1,011
XMP.339 (170)	DAB - DAB - 153 - 157 - DAB - DAB	74	2,878

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone*
XMP.339P <sup>f</sup> (170)	DAB - DAB - 153 - 157 - DAB - DAB	98	2,599
XMP.340 (171)	p-amino-F - p-amino-F - 153 - 157 - p- amino-F - p-amino-F	66	b
XMP.340P <sup>f</sup> (171)	p-amino-F - p-amino-F - 153 - 157 - p- amino-F - p-amino-F	94	b
XMP.341 (172)	PYR - PYR - 153 - 157 -PYR - PYR	76	b
XMP.341P <sup>f</sup> (172)	PYR - PYR - 153 - 157 -PYR - PYR	99	b
XMP.342 (173)	K <sub>D</sub> - K <sub>D</sub> - 153 - 157 - K <sub>D</sub> - K <sub>D</sub>	72	1,591
XMP.342P <sup>f</sup> (173)	K <sub>D</sub> - K <sub>D</sub> - 153 - 157 - K <sub>D</sub> - K <sub>D</sub>	97	700
XMP.343 (174)	K - K - 153 - 157 - K - K, V @ 153 (W)	69	NT
XMP.344 (175)	K - K - 153 - 157 - K - K, A @ 154 (L)	71	NT
XMP.345 (176)	K - K - 153 - 157 - K - K, A @ 157 (L)	72	NT

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.346 (177)	K - K - 153 - 157 - K - K, p-Amino-F @ 153 (W)	90	NT
XMP.347 (178)	K - K - 153 - 157 - K - K, $\beta$ (2-naphthyl) A <sub>D</sub> @153 (W), L @ 156 (Q)	82	NT
XMP.348 (179)	K - K - K - 153 - 157 - K - K	69	NT
XMP.349 (180)	K - K - 153 - 157 - K - K - K	67	NT
XMP.350 (181)	K - K - K - 153 - 157 - K - K - K	65	NT
XMP.351 (182)	K - K - 153 - 158 - K - K	59	NT
XMP.351P' (182)	K - K - 153 - 158 - K - K	98	405
XMP.352 (183)	K - K - 153 - 161	66	NT
XMP.352P' (183)	K - K - 153 - 161	98	381
XMP.353 (184)	P - 153 - 161*	66	3,093

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.353P' (184)	P - 153 - 161*	99	411
XMP.354 (185)	† P - 153 - 161*	72	NT
XMP.355 (186)	P - 153 - 161	67	2,529
XMP.355P' (186)	P - 153 - 161	99	299
XMP.356 (187)	† P - 153 - 161	58	NT
XMP.357 (188)	K - 153 - 160 - P		NT
XMP.358 (189)	K - K - 153 - 160 - P		NT
XMP.359 (190)	C <sub>D</sub> - 153 - 161		NT
XMP.360 (191)	K <sub>D</sub> - C <sub>D</sub> - 154 - 158 - C - K <sub>D</sub>		NT
XMP.361 (192)	K <sub>D</sub> - C - 154 - 158 - C - K <sub>D</sub>		NT
XMP.362 (193)	K <sub>D</sub> - K- C - 154 - 158 - C - K - K <sub>D</sub>		NT
XMP.363 (194)	K <sub>D</sub> - W <sub>D</sub> - 154 - 159 - K <sub>D</sub> - K <sub>D</sub>	68	1,015

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.363P <sup>f</sup> (194)	K <sub>D</sub> - W <sub>D</sub> - 154 - 159 - K <sub>D</sub> - K <sub>D</sub>	97	709
XMP.364 (195)	† K <sub>D</sub> - W <sub>D</sub> - 154 - 159 - K <sub>D</sub> - K <sub>D</sub>	62	NT
XMP.365 (196)	K <sub>D</sub> - W <sub>D</sub> - L <sub>D</sub> - I <sub>D</sub> - Q <sub>D</sub> - L <sub>D</sub> - F <sub>D</sub> - H <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	66	1,294
XMP.365P <sup>f</sup> (196)	K <sub>D</sub> - W <sub>D</sub> - L <sub>D</sub> - I <sub>D</sub> - Q <sub>D</sub> - L <sub>D</sub> - F <sub>D</sub> - H <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	97	544
XMP.366 (197)	† K <sub>D</sub> - W <sub>D</sub> - L <sub>D</sub> - I <sub>D</sub> - Q <sub>D</sub> - L <sub>D</sub> - F <sub>D</sub> - H <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	54	NT
XMP.367 (198)	K <sub>D</sub> - K <sub>D</sub> - H <sub>D</sub> - F <sub>D</sub> - L <sub>D</sub> - Q <sub>D</sub> - I <sub>D</sub> - L <sub>D</sub> - W <sub>D</sub> - K <sub>D</sub>	69	4,641
XMP.368 (199)	† K <sub>D</sub> - K <sub>D</sub> - H <sub>D</sub> - F <sub>D</sub> - L <sub>D</sub> - Q <sub>D</sub> - I <sub>D</sub> - L <sub>D</sub> - W <sub>D</sub> - K <sub>D</sub>		NT
XMP.369 (200)	152-161, K @ 152(G), ORN @ 156 (Q)	60	993

TABLE 1 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>C. albicans</i> pmol/ 30 mm <sup>2</sup> zone <sup>a</sup>
XMP.370 (201)	† 152-161, K @ 152(G), ORN @ 156 (Q)		NT
XMP.371 (202)	152-161, K @ 152 (G), DAB @ 156 (Q)	74	843
XMP.372 (203)	† 152-161, K @ 152 (G), DAB @ 156(Q)		NT
XMP.373 (204)	† 152-161, K @ 152 (G)		NT

<sup>a</sup> pmoles of peptide added to well to achieve a 30 mm<sup>2</sup> zone as determined by PROBIT analysis  
<sup>b</sup> No detectable activity up to 5 µg/well  
<sup>c</sup> NT = not tested  
<sup>d</sup> † = peptide has an acetylated amino terminus; \* = peptide has a non-amidated carboxy-terminus  
<sup>e</sup> Abbreviations: X<sub>D</sub> refers to a D-amino acid; ORN is ornithine; DAB is diamino butyric acid; PYR is pyridinyl-alanine (free acid)  
<sup>f</sup> "P" refers to XMP peptide purified as described in Example 1



## Example 3

IN VITRO AND IN VIVO EFFECT OF ANTI-FUNGAL PEPTIDES  
ON A VARIETY OF FUNGAL SPECIES

5 This example addresses *in vitro* and *in vivo* screening of various Domain III derived peptides for anti-fungal activity against a number of fungal species, including *Candida* species and strains resistant to various anti-fungal agents, in a radial diffusion assay. The example also addresses the effects of combinations of peptide and amphotericin B against *Candida* strain SLU-1.

10 Domain III derived peptides were tested for their fungicidal activity on amphotericin resistant *Candida*. Resistant colonies of *Candida* were isolated using a gradient plate technique. A slanted Sabouraud dextrose agar plate was poured and allowed to harden. The plate was made level and additional agar supplemented with nystatin (Sigma, St. Louis, MO, cat. no. N-3503) at a concentration of 10  $\mu\text{g/mL}$  was poured. Cells from the the CA-1 colony of *Candida albicans* SLU-1 strain described in Example 2 ( $10^7$  cells in a volume of 100  $\mu\text{L}$ ) were spread over the plate and incubated at 37°C overnight. Initially, minute colonies were seen and required additional incubation time to achieve the size of wildtype colonies. Eleven colonies were designated SLU-2A though SLU-2K. These colonies were serially passaged in Sabouraud dextrose broth supplemented with increasing concentrations of amphotericin B, after an initial passage with 2  $\mu\text{g/mL}$  amphotericin B. After the final passage in 20  $\mu\text{g/mL}$  amphotericin B, colonies 2G, 2H, 2J and 2K remained viable whereas the wildtype SLU-1 strain remained sensitive to 1  $\mu\text{g/mL}$  amphotericin B. None of the resistant strains demonstrated germ tube formation in fetal bovine serum. In addition, these isolates had a much slower growth rate than SLU-1 and did not form hyphae at 37°C.

25 For the radial diffusion assays, *Candida albicans* SLU-1 were grown as described above and SLU-2G were grown overnight in Sabouraud dextrose broth supplemented with 10  $\mu\text{g/mL}$  amphotericin B and 5  $\mu\text{g/mL}$

30

ceftriaxone at 37°C. Cultures were diluted 1:25 into fresh, unsupplemented broth and allowed to grow for 5 hours at 37°C. Cells were pelleted at 1,500 X g for 5 minutes at 4 °C. Supernatant was decanted and replaced with 5 mL of 10 mM phosphate buffer, pH 7.4. After centrifugation the cell pellets were resuspended with 5 mL phosphate buffer for an OD<sub>570</sub> determination. One OD<sub>570</sub> for SLU-1 cells was 3 X 10<sup>7</sup> CFU/mL and for SLU-2G cells was 5 X 10<sup>6</sup> CFU/mL.

Cells were added to 10 mL of molten, cooled (~ 45°C) underlayer agarose to a concentration of 1 X 10<sup>6</sup>/mL and the suspension was poured into a level square petri plate with gentle rocking to allow even distribution and solidification to a uniform thickness of about 1 mm. Wells were cut into the hardened agarose with a sterilized, 3 mm diameter punch with vacuum.

Peptides were two-fold serially diluted with D-PBS from a starting concentration of approximately 1 mg/mL. Amphotericin B and nystatin were similarly diluted starting at 100 and 225 µg/mL, respectively. Five µL were added per well and allowed to diffuse at 37°C for 1.5-2.0 hours. Then 10 mL of molten overlayer agarose were added and the plates were incubated inverted at 37°C overnight. Plates were stained with a dilute Coomassie solution, inhibition zones were measured with calipers and net areas were calculated, then converted to pmol values by PROBIT analysis. The results of a representative experiment are shown in Figure 2A for the SLU-1 strain and Figure 2B for the SLU-2G strain. In Figures 2A and 2B, the fungicidal activity is represented for XMP.13 as open circles; for XMP.37 as closed circles; for XMP.97 as open triangles; for XMP.127 as closed triangles; for amphotericin B as open squares; and for nystatin as closed squares. The pmol for a 30 mm<sup>2</sup> zone of inhibition were calculated to be: for XMP.13, 689 pmol against SLU-1 and 129 pmol against SLU-2G; for XMP.37, 231 pmol against SLU-1 and 75 pmol against SLU-2G; for XMP.97, 670 pmol against SLU-1 and 161 pmol against SLU-2G; for

XMP.127, 935 pmol against SLU-1 and 116 pmol against SLU-2G; for amphotericin B, 36 pmol against SLU-1 and >541 pmol for SLU-2G; and for nystatin, 98 pmol against SLU-1 and >1,215 pmol against SLU-2G. As shown in Figures 2A and 2B, representative Domain III derived peptides XMP.13, XMP.37, XMP.97 and XMP.127 demonstrated fungicidal activity against both the SLU-1 wild type strain and the SLU-2G amphotericin B-resistant strain, with better activity demonstrated against the SLU-2G amphotericin B resistant strain. In contrast, amphotericin B was effective against the original SLU-1 strain but did not kill the SLU-2G resistant cells. These results demonstrate that Domain III derived peptides according to the invention are effective fungicidal agents by a mechanism different from that of amphotericin B.

Further experiments were performed to determine the anti-fungal activity of Domain III derived peptides on commercially-available strains of *Candida* considered resistant to other anti-fungal agents: polyene-resistant *C. albicans* (ATCC Accession No. 38247), 5-fluorocytosine-resistant *C. albicans* (ATCC No. 44373), azole-resistant *C. albicans* (ATCC No. 62342), and ketoconazole-resistant *C. albicans* (ATCC No. 64124). Fungicidal activity of representative peptides XMP.13, XMP.36, XMP.97, XMP.127, and XMP.166 was not reduced on the above strains tested, indicating that the peptides are effective by a mechanism different than that of the other anti-fungal agents.

The anti-fungal activity of Domain III derived peptides was also evaluated *in vitro* against a variety of fungal species, including *Candida glabrata*, *Candida krusei*, *Candida lusitanae*, *Candida parapsilosis*, and *Candida tropicalis*. For these experiments, one colony of each of the above-listed *Candida* strains was picked from a Sabouraud's dextrose agar (SDA) plate and inoculated into 5 mL of Sabouraud's dextrose broth (SDB, 2% dextrose and 1% neopeptone) or, for *C. krusei*, Yeast Malt broth (YM, Becton Dickenson, Cockeysville, MD, cat no. BL11405) in 12 mL

polypropylene snap-cap tubes. The tube cultures were incubated overnight with shaking at 37°C.

Cultures were harvested when the OD<sub>570</sub> of a 1:10 dilution was greater than or equal to the following values: 0.083 for *Candida glabrata*, 0.154 for *Candida krusei*, 0.117 for *Candida lusitanae*, 0.076 for *Candida parapsilosis*, and 0.192 for *Candida tropicalis*. Cells were centrifuged for 7 minutes in an Eppendorf microfuge at 3,000 rpm (about 1,500 g). The cell pellet was resuspended in 1 mL PBS and approximately 1 X 10<sup>7</sup> cells in about 0.5 mL were added to 10 mL of cooled underlay agar (3 % SBD, 1 % agarose, 0.02% Tween 20, 10 mM sodium phosphate buffer, pH 7.4 at about 45°C). The suspension was poured into square petri plates, allowed to solidify, and wells cut as described above.

Peptides were two-fold serially diluted with D-PBS from about 20 µL of a starting concentration of approximately 1 mg/mL. Five µL of peptide dilution were added per well and allowed to diffuse for at least about 30 minutes into the agar at 37°C (to allow complete diffusion). Then 10 mL of molten overlayer agarose (6% SDB, 1 % agarose, 10 mM sodium phosphate buffer, pH 7.4 at about 45°C) were added and the plates were incubated inverted at 37°C overnight. Plates were stained with a dilute Coomassie solution, inhibition zones were measured with calipers and net areas were calculated, then converted to pmole values by PROBIT analysis. The results of a representative experiment are shown in Table 2. Exemplary Domain III derived peptides XMP.13P, XMP.97P, XMP.127P, XMP.166P, XMP.286P, XMP.327P, XMP.331P, XMP.332P, XMP.333P and XMP.337P demonstrated some fungicidal activity against at least several of the *Candida* strains tested. These results demonstrate that Domain III derived peptides according to the invention are effective fungicidal agents in a broad spectrum against a variety of *Candida* species.

TABLE 2

Anti-fungal activity: pmol/30 mm <sup>2</sup> zone <sup>a,d</sup>						
	<i>Candida albicans</i>	<i>Candida glabrata</i>	<i>Candida krusei</i>	<i>Candida lusitanae</i>	<i>Candida parapsilosis</i>	<i>Candida tropicalis</i>
XMP.13P <sup>e</sup>	2,233	1,022	1,747	746	1,502	452
XMP.97P <sup>e</sup>	2,019	1,786	907	900	868	193
XMP.127P	2,144	779	878	551	711	373
XMP.166	>3,079	2,100	3,240	1,133	1,199	864
XMP.286P <sup>e</sup>	NT <sup>e</sup>	1,843	1,558	1,235	1,134	606
Amphotericin B	11	<17	120	35	91	108
XMP.327P <sup>e</sup>	5,108	>6,295	3,327	120	119	2,598
XMP.331P <sup>e</sup>	b	b	>5,467	1,500	1,451	b

TABLE 2 (continued)

	Anti-fungal activity: pmol/30 mm <sup>2</sup> zone <sup>a,d</sup>				
	<i>Candida albicans</i>	<i>Candida glabrata</i>	<i>Candida krusei</i>	<i>Candida lusitanae</i>	<i>Candida parapsilosis</i> <i>Candida tropicalis</i>
XMP.332P <sup>e</sup>	3,931	2,190	2,802	<219	170 866
XMP.333P <sup>e</sup>	5,191	4,040	4,101	174	209 2,894
XMP.337P <sup>e</sup>	b	b	5,339	6,928	b b

- a     pmol of peptide added to well to achieve a 30 mm<sup>2</sup> zone as determined by PROBIT analysis  
b     No detectable activity up to 5 µg/well  
c     NT = not tested  
d     Actual pmol values obtained are dependent on assay conditions; values in this Table for *C. albicans* higher than those presented in Table 1 due to higher effective concentration of agarose during incubation  
e     "P" refers to XMP peptide purified as described in Example 1

The effects of combinations of peptide and amphotericin B against *Candida* strain SLU-1 were studied. For these experiments, *Candida albicans* SLU-1 was grown and assayed in a broth dilution assay as described in Example 2, except that peptide alone, amphotericin B alone, or combinations of peptide and amphotericin B were incubated with the fungal cells for testing.

The results of such an assay using representative peptide XMP.97, alone or in combination with amphotericin B, are shown in Figure 3. In Figure 3, the fungicidal activity of combinations of XMP.97 and amphotericin B are represented for the XMP.97 concentrations shown and concentrations of amphotericin B of 0.047  $\mu\text{g/ml}$  (open squares); 0.074  $\mu\text{g/ml}$  (closed triangles); 0.188  $\mu\text{g/ml}$  (open triangles); 0.375  $\mu\text{g/ml}$  (closed circles); and 0.750  $\mu\text{g/ml}$  (open circles). The activity of XMP.97 alone is represented by the closed squares. Both XMP.97 and amphotericin B are each effective alone at certain concentrations as anti-fungal agents. The combination of peptide and amphotericin B does not result in inhibition (as it would if the two drugs were antagonistic), but rather results in decreasing the amount of both anti-fungal agents required for maximum killing. In particular, concurrent administration of this Domain III derived peptide with an anti-fungal agent, such as amphotericin B, achieved an improved therapeutic effectiveness through reducing the concentration of amphotericin B required to eradicate or inhibit fungal growth. Because the use of amphotericin B has been limited by its systemic toxicity, lowering the concentration of such an anti-fungal agent required for therapeutic effectiveness can reduce toxicity, and thus may allow wider use of this agent.

The anti-fungal activity of Domain III derived peptides may also be evaluated *in vivo* in animal models for a variety of fungal species, including *Cryptosporidium parvum*, *Cryptococcus neoformans* and *Histoplasma capsulatum*. Animal models for *C. parvum*, sponsored by contract resources from the National Institute of Allergy and Infectious Diseases, include severe



combined immunodeficiency (SCID) mouse models and a colostrum-deprived SPF piglet model.

#### Example 4

##### 5                    *IN VIVO* ANTI-FUNGAL EFFECT OF PEPTIDES IN MICE WITH SYSTEMIC *CANDIDA* INFECTION

10                    This example addresses the *in vivo* anti-fungal effect of Domain III derived peptides in mitigating the total mortality or mortality rate of mice systemically infected with *Candida albicans*. Peptides that had been screened for anti-fungal activity in the radial diffusion and broth assays described in Example 2 were prepared and purified as described in Example 1.

15                    Groups of 15 male DBA/2J mice at age 6-8 weeks (Jackson Laboratory, Bar Harbor, ME) were inoculated with  $1.24 \times 10^5$  *C. albicans* (SLU-1 strain as described in Example 2) by intravenous injection into the tail vein. Cells were prepared for animal injection as follows. A single colony was selected and used to inoculate a 5 mL tube of Sabouraud dextrose broth. Incubation was at 30°C with shaking to allow aeration for a period of 15-18 hours. Four mL of the overnight culture were added to 100 mL of fresh Sabouraud dextrose broth (1:25 dilution) and incubated for 4 hours. The 100 mL culture was pelleted at 1,500 X g for 5 minutes. Cells were washed twice by adding 20 mL D-PBS, vortexing and re-centrifuging. Cells were collected in one tube and a sample is diluted 1:10 to be measured by OD<sub>570</sub> (1 OD unit =  $3 \times 10^7$  CFU/mL). The cells were diluted to the desired dose in D-PBS and kept at 4°C until used. Doses were confirmed by performing serial ten-fold dilutions and plating 50 µl per dilution on Sabouraud dextrose agar. Colonies were counted the following day after overnight incubation at 37°C. A 500 mL culture yielded approximately  $1 \times 10^9$  CFU/mL.

30                    A *Candida* inoculation of approximately  $1 \times 10^5$  cells resulted in an LD<sub>50</sub> over 28 days in this model. Immediately after fungal challenge, the mice were intravenously injected via the tail vein with a 0.1 mL volume

of 10 mg/kg XMP.36, 5 mg/kg XMP.97, 10 mg/kg XMP.102, 1 mg/kg amphotericin B (Sigma, St. Louis, MO), or phosphate buffered saline (PBS) as a control. Treatment with the same amounts of peptides, amphotericin B or PBS was repeated at Day 2 and Day 4 (except that the second dose of XMP.36 was given at a dose of 5 mg/kg). Mice were monitored twice daily for mortality until termination of the study at Day 28. The mortality data, displayed in Figure 4, show that 100% of the mice treated with amphotericin B survived, 53% of mice treated with XMP.97 survived ( $p < 0.05$  compared to control), 33% of mice treated with XMP.36 survived, 27% of mice treated with XMP.102 survived, and 20% of mice treated with PBS survived until Day 28. In Figure 4, the symbol "X" represents survival after treatment with amphotericin B; open squares, treatment with XMP.97; open circles, treatment with XMP.36; open diamonds, treatment with XMP.102; and open triangles, treatment with buffer. Statistical significance was evaluated using the Lifetest Survival Curve analysis. [Lawless, *Statistical Models and Methods for Lifetime Data*, John Wiley & Sons, New York (1982).] The duration and almost linear decline in survival is analogous to human opportunistic candidiasis.

In additional 3-dose studies, groups of 15 mice were injected with a fungal challenge of  $0.5 \times 10^5$  *Candida* cells, prepared for injection as described above, followed by treatment at Day 0, Day 2 and Day 5 with a 0.1 mL volume of 10 mg/kg XMP.127, 5 mg/kg XMP.13, 5 mg/kg XMP.37, 1 mg/kg amphotericin B, or PBS as a control. The mortality data are displayed in Figure 5; 100% of the mice treated with amphotericin B survived, 67% of mice treated with XMP.127 survived ( $p < 0.05$  compared to control), 33% of mice treated with XMP.37 survived, 20% of mice treated with XMP.13 survived, and 33% of mice treated with PBS survived until Day 28. In Figure 5, the symbol "X" represents survival after treatment with amphotericin B; open circles, treatment with XMP.127; filled triangles, treatment with buffer;

open squares, treatment with XMP.37; open triangles, treatment with XMP.13.

In these 3-dose studies, amphotericin B was completely protective, as expected. The effect of XMP.102, a control peptide without anti-fungal activity as determined by a radial diffusion assay as described in Example 2, was no different from PBS. The data demonstrate that administration of peptides XMP.97 and XMP.127 to mice challenged systemically with *C. albicans* unexpectedly provided a significant reduction in mortality compared with buffer-treated controls.

Further studies to determine the effectiveness of anti-fungal peptides were performed at an increased dosing regimen (6 doses rather than 3 doses as described above). Groups of 9 week-old male DBA/2J mice were inoculated with concentrations of  $2.7 \times 10^5$  *Candida* cells (prepared as described above) by intravenous injection in the tail vein. Immediately after fungal challenge, the mice were treated with a 0.1 mL volume of 10 mg/kg XMP.284, 1 mg/kg amphotericin B or PBS as a control at Day 0, Day 2, Day 4, Day 7, Day 9 and Day 11. All amphotericin B-treated animals were protected. The results for XMP.284 (closed circles) and PBS control (open circles) are displayed in Figure 6. The mortality data showed that only one of the PBS-treated animals survived injection with  $2.7 \times 10^5$  *Candida* at Day 6 through Day 24 (6% survival), however, XMP.284 protected 13 animals (87% survival) at Day 6 and 3 animals (33% survival) at Day 24.

Studies were also performed to determine the effectiveness of representative anti-fungal peptides in cyclosporin A-immunosuppressed mice systemically infected with *Candida albicans* SLU-1. Groups (15 animals/group) of 9 week-old male DBA/2J mice were immunosuppressed by pretreatment with 10 mg/kg (Day-1) of cyclosporin A administered by intraperitoneal injection. One day later (Day 0), the mice were inoculated with  $2 \times 10^5$  *Candida* cells by intravenous injection in the tail vein. Immediately after fungal challenge, the mice were treated with a 0.1 mL

volume of 10 mg/kg XMP.284, 10 mg/kg XMP.127, or PBS as a control. Cyclosporin A injections were repeated at Day 1, Day 3, Day 7, and Day 9. XMP.284, XMP.127 or PBS injections were repeated at Day 2, Day 4, Day 6, Day 8 and Day 10. All amphotericin B-treated animals were protected. The results displayed in Figure 7 of the mortality data after treatment with XMP.127 (closed triangles), XMP.284 (open squares) and PBS control (open circles) show that the immunosuppressed mice are more susceptible to *Candida* infection as expected. However, XMP.284 and to a lesser extent XMP.127, provided protection against the infection as measured by increased survival compared with PBS controls.

Further *in vivo* experiments with or without cyclosporin A immunosuppression are performed to confirm the *in vitro* anti-fungal activity of peptides as described in Example 3 on strains of *Candida* considered resistant to other anti-fungal agents: polyene-resistant *C. albicans* (ATCC Accession No. 38247), 5-fluorocytosine-resistant *C. albicans* (ATCC No. 44373), azole-resistant *C. albicans* (ATCC No. 62342), and ketoconazole-resistant *C. albicans* (ATCC No. 64124).

### Example 5

#### SERUM STABILITY ASSAYS

This example addresses the serum stability of Domain III derived peptides and the effect of serum degradation using HPLC and bioassay.

For these serum stability experiments, peptides were prepared by solid phase peptide synthesis and purified to 94% or greater purity as described in Example 1. Blood was collected from metaphane anesthetized rats by aortic bleed into Vacutainer™ tubes and allowed to clot at room temperature for approximately 30 minutes, then centrifuged at 3000 rpm (about 1000 X g) for 10 minutes at room temperature and the serum aspirated. In addition, frozen human serum (North American Biologics, Inc., Miami,

FL, cat. no. 2140, lot no. 94115) was thawed at room temperature and filtered through a 0.45  $\mu$ m membrane before use.

A 1 mg/mL solution of an exemplary XMP peptide to be tested was added to an equal volume of either rat or human serum described above and maintained at 37°C. At 0, 1, 2, and 4 hours, 100  $\mu$ L were removed and processed by solid phase extraction for HPLC analysis as follows. Serum samples were prepared for HPLC using C-18 Sep-Pak cartridges (1 mL cartridge with 100 mg of sorbent, Waters Corp., Milford, MA). One hundred  $\mu$ L of serum sample were added to an equal volume of 1 % TFA and mixed for 30 seconds on a Vortex mixer. The sample was then applied to a C-18 Sep-Pak cartridge that had been conditioned by washing with 1 mL of methanol followed by 1 mL Milli-Q water. Weakly retained components were eluted by washing with 1 mL of 0.1 % TFA. The bound peptide was eluted with two volumes of 250  $\mu$ L 80 % acetonitrile/0.065 % TFA.

The material eluted from the Sep-Pak cartridge was analyzed on a Michrom Ultrafast Microprotein Analyzer equipped with a 150 mm X 1 mm, 5  $\mu$  particle, 300 Å pore C-8 Zorbax column. The column oven was set to 40°C, the flow rate was 100  $\mu$ L/minute, and injection volumes were typically 5-10  $\mu$ L. HPLC was performed using 5 % acetonitrile/0.1 % TFA in water as mobile phase A, and 80 % acetonitrile/0.065 % TFA as mobile phase B. The eluate was monitored spectrophotometrically at 214 nm. Peptide standards were dissolved in mobile phase A at 0.1 mg/mL. The gradient was 25-35 % B/10 minutes followed by a 5 minute wash step of 100 % B and reequilibration at 25 % B for 10 minutes.

The peptides identified and purified after serum incubation as described above were subjected to N-terminal peptide sequencing performed on an Applied Biosystems Model 477A/120A sequencer and to electrospray ionization mass spectrometry (ESI/MS) performed using a VG Biotech Bio-Q Mass Spectrometer. In addition, the peptides identified and purified after serum incubation as described above were also tested for their anti-fungal

activity in a radial diffusion bioassay with *Candida albicans* SLU-1 strain as described in Example 2.

For these experiments, representative Domain III derived peptides XMP.97, XMP.327, XMP.332 and XMP.333 were used. The serum stability of each differed substantially. For example, XMP.97 was degraded in serum with a half-life of 59 minutes under the described assay conditions. Two metabolites of XMP.97 were detected and were determined to be cleavage products where the cleavage at the amino terminus yielded peptides shortened by either one or two amino acids. The degradation products and kinetics were similar for commercially obtained human serum or freshly prepared rat serum. Other metabolic products of XMP.97 were presumably present but in concentrations below detection limits.

The chemical changes observed after serum incubation of a peptide were generally accompanied by a loss in activity as determined in the radial diffusion assay with *Candida*. For example, XMP.327 was degraded with a serum half-life of 40 minutes under the described HPLC assay conditions. The serum half-life of XMP.327 as determined by anti-fungal activity in the radial diffusion assay was 43 minutes. In other cases, there may be a difference between the rate of disappearance of anti-fungal activity and the rate of peptide disappearance, indicating that certain metabolites may have activity.

The enzymes responsible for peptide degradation were not specifically identified in these experiments. However, aminopeptidases present in serum are capable of removing one or more residues from the N-terminus of peptides. [See, e.g., Hooper, N.M., Ectopeptidases, in Biological Barriers to Protein Delivery, pp.23-50, eds., Audus and Raub, Plenum Press, New York, 1993]. Aminopeptidase N (EC 3.4.11.2), for example, has a broad substrate specificity, releasing the N-terminal amino acid from unblocked peptides. Based on sites of potential hydrolysis, peptides can be designed to minimize certain degradation pathways. Serum degradation at

specific amino acids within a peptide may be avoided by incorporation of D-amino acids or other atypical amino acids, and/or by cyclization to prevent protease recognition.

5 In additional studies, peptides were designed to have increased serum stability. For example, peptides were synthesized using one or more D-amino acids. Also, peptides were synthesized and then their N-terminus was acetylated as described in Example 1. For example, XMP.333 was synthesized having the same amino acid sequence as XMP.327, except that the amino-terminal lysine residue used for synthesis was a D-amino acid. When  
10 XMP.333 was tested, its serum half-life as determined in the radial diffusion assay was 130 minutes (as compared with 43 minutes for XMP.327). These results indicate that a single D-amino acid at the N-terminus prevents some degradation and increases the half-life of the peptide.

Peptide constructs can be prepared with increased half-life, but  
15 may not maintain the same *in vitro* activity. For example, XMP.327 had a serum half-life of 43 minutes and activity in radial diffusion of 353 pmol (see Table 1). Peptide XMP.331 having the same amino acid sequence of XMP.327 but having an acetylated N-terminus, had an increased serum half-life of 280 minutes as detected by HPLC analysis, but a decreased activity of  
20 >3,493 pmol (see Table 1) as compared with the non-acetylated XMP.327. However, even with decreased *in vitro* activity, such a peptide may have increased efficacy *in vivo* due to its increased stability.

Other peptide constructs can be prepared with not only significantly increased stability but also with maintained anti-fungal activity  
25 in the radial diffusion assay. For example, XMP.332 was synthesized using all D-amino acids and is the inverse sequence of XMP.327. Such a "retro-D" peptide should be resistant to serum enzymes that recognize and hydrolyze the peptide bond between L-amino acids. In fact, XMP.332 did not show any  
30 decrease in activity or decrease in peptide concentration over a 6 hour period of serum incubation. Such a peptide construct, which can maintain the *in*



*vitro* equivalent molar activity to its L-amino acid peptide counterpart and shows increased serum half-life, may have increased efficacy *in vivo*.

### Example 6

5

#### STRUCTURE/FUNCTION STUDIES

This example addresses the design and assay of anti-fungal peptides for structural motif and minimum functional sequence analysis.

10

As shown in Examples 2, 3, and 4 above, XMP.97 was determined to have significant *in vitro* activity against *C. albicans* and significant *in vivo* activity in a mouse systemic candidiasis model. The sequence was derived from XMP.13 with a lysine substitution for glycine at position 152 in the BPI sequence. As shown in Example 5, sequential N-terminal amino acid removal was observed when the peptides, including XMP.97, were incubated with serum. The 13 amino acid peptide XMP.284 (SKVKWLIQLFHKK-amide; SEQ. ID. NO:117) was synthesized, purified (97%) and tested for anti-fungal activity. The *in vitro* activity was surprisingly not appreciably diminished (see Table 1). A deletion series of 35 peptides was generated from this starting sequence. All possible N- and C-terminal deletion 12-mers through 6-mers (XMP.285-XMP.319) were synthesized as shown in Table 3 below.

20

25

30

Crude peptides were assayed for an initial purity as described in Example 1 and for *in vitro* activity with the radial diffusion fungicidal assay as described in Example 2. The nmol value shown in Table 3 represents a calculated value (log titration curve) for the number of nanomoles required to achieve a net 30 mm<sup>2</sup> zone in the assay. In purifying XMP.97 and XMP.284, a significant change was observed in the pmol value upon purification. The magnitude of change was larger than observed with other crude peptides and was likely due to removal of inactive peptide impurities. Thus, final comparisons were made using peptides purified as described in Example 1, and preferably assayed on the same day.



The most active crude peptides were purified by HPLC and re-assayed. The results are shown in Table 3. From this analysis, as demonstrated by Table 3, XMP.293 was the smallest peptide with an increase in molar activity relative to peptide XMP.97. XMP.297 was also equivalent to XMP.284 in activity. Interestingly, XMP.298 was within two-fold of XMP.297. Activity was demonstrable even with 6 amino acid peptides, such as XMP.315, however, this level of activity was decreased by about 3 orders of magnitude compared with the activity of the starting sequence.

These data demonstrate that one group of Domain III derived peptides of the invention are described and defined by a structural motif consisting of a core of 4 to 6, preferably 5 to 6, amino acids where the core contains one neutral hydrophilic residue in the middle of hydrophobic amino acids, and where the core is bounded or flanked at the N- and/or C-terminus by cationic amino acids. Preferred core sequences include: LIQL, IQLF, WLIQF, LIQLF and WLIQLF. Preferred cationic amino acids include: K (most preferred), R, H, ornithine (ORN) and diaminobutyric acid (DAB). Peptides with such a motif possess optimal activity. Activity was observed, but was somewhat diminished, when the peptide contained all of the cationic residues on the C-terminus (*e.g.*, XMP.298) or on the N-terminus (*e.g.*, XMP.300) of the core. Peptides XMP.320 - XMP.368 were designed and prepared consistent with this motif, and provide additional support for the structural motif and minimum functional characterization sequence of anti-fungal peptides according to the invention.

25

30

TABLE 3

Length in a.a. <sup>c</sup>	Peptide	MW	AMINO ACID SEQUENCE														Plate Assay (nmol) <sup>b</sup>	Crude Purity (%)	Plate Assay (nmol) <sup>c</sup>
			148	149	150	151	152 <sup>ab</sup>	153	154	155	156	157	158	159	160	161			
14	97	1782	K	S	K	V	K	W	L	I	Q	L	F	H	K	K	0.701	68	0.304
13	284	1654	.	S	K	V	K	W	L	I	Q	L	F	H	K	K	1.460	60	0.373
12	285	1526	.	S	K	V	K	W	L	I	Q	L	F	H	K	.	>3.024	75	
	286	1527	.	.	K	V	K	W	L	I	Q	L	F	H	K	K	1.216	61	0.253
11	287	1398	.	S	K	V	K	W	L	I	Q	L	F	H	.	.	>3.509	58	
	288	1439	.	.	K	V	K	W	L	I	Q	L	F	H	K	.	3.639	78	0.279
	289	1439	.	.	.	V	K	W	L	I	Q	L	F	H	K	K	1.542	78	0.68
10	290	1261	.	S	K	V	K	W	L	I	Q	L	F	.	.	.	>2.233	79	
	291	1311	.	.	K	V	K	W	L	I	Q	L	F	H	.	.	>5.039	55	
	292	1311	.	.	.	V	K	W	L	I	Q	L	F	H	K	.	>4.063	78	
	293	1340	.	.	.	.	K	W	L	I	Q	L	F	H	K	K	1.156	78	0.215

TABLE 3 (continued)

Length in a.a. <sup>a</sup>	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) <sup>b</sup>	Crude Purity (%)	Plate Assay (nmol) <sup>c</sup>
			148	149	150	151	152 <sup>ab</sup>	153	154	155	156	157	158	159	160	161		
9	294	1113	.	S	K	V	K	W	L	I	Q	L	.	.	.	.	63	>4.634
	295	1174	.	.	K	V	K	W	L	I	Q	L	F	.	.	.	82	>1.977
	296	1183	.	.	.	V	K	W	L	I	Q	L	F	II	.	.	.64	>5.573
	297	1212	.	.	.	.	K	W	L	I	Q	L	F	II	K	.	81	1.817
	298	1212	.	.	.	.	.	W	L	I	Q	L	F	II	K	K	84	2.628
8	299	1000	.	S	K	V	K	W	L	I	Q	.	.	.	.	.	68	>8.768
	300	1026	.	.	K	V	K	W	L	I	Q	L	.	.	.	.	75	1.957
	301	1045	.	.	.	V	K	W	L	I	Q	L	F	.	.	.	41	--
	302	1083	.	.	.	.	K	W	L	I	Q	L	F	II	.	.	75	>5.497
	303	1083	.	.	.	.	.	W	L	I	Q	L	F	II	K	.	78	>4.694
	304	1025	.	.	.	.	.	.	L	I	Q	L	F	II	K	K	84	>8.290

TABLE 3 (continued)

Length in a.a.	Peptide	MW	AMINO ACID SEQUENCE													Plate Assay (nmol) <sup>b</sup>	Crude Purity (%)	Plate Assay (nmol) <sup>c</sup>
			148	149	150	151	152 <sup>ab</sup>	153	154	155	156	157	158	159	160	161		
7	305	872.1	.	S	K	V	K	W	L	I	.	.	.	.	.	.	73	> 10.228
	306	913.2	.	.	K	V	K	W	L	I	Q	.	.	.	.	.	62	> 10.485
	307	898	.	.	.	V	K	W	L	I	Q	L	.	.	.	.	67	> 8.345
	308	946	.	.	.	.	K	W	L	I	Q	L	F	.	.	.	72	--
	309	955	.	.	.	.	.	W	L	I	Q	L	F	II	.	.	76	--
	310	897	.	.	.	.	.	.	L	I	Q	L	F	II	K	.	56	> 9.475
	311	912	.	.	.	.	.	.	.	I	Q	L	F	II	K	K	77	--



## Example 7

## LPS NEUTRALIZATION ACTIVITY OF ANTI-FUNGAL PEPTIDES

5 This example addresses the *in vitro* and *in vivo* LPS neutralizing activity of Domain III derived peptides.

10 An *in vitro* LPS neutralization screening assay for evaluation of Domain III derived peptides was developed (as described in co-owned and co-pending U.S. Patent Application Serial No. 08/306,473) which provides both a measure of efficacy of each peptide ( $EC_{50}$ ) and of the toxicity/growth inhibition of each peptide ( $IC_{50}$ ). This sensitive assay for inhibition of cellular proliferation in mouse cells treated with LPS can also be utilized for quantitation of LPS levels in human plasma upon development of a standard curve.

15 In this assay, mouse RAW 264.7 cells (ATCC Accession No. T1B71), maintained in RPMI 1640 medium (GIBCO), supplemented with 10mM HEPES buffer (pH 7.4), 2mM L-glutamine, penicillin (100U/mL), streptomycin (100 $\mu$ g/mL), 0.075% sodium bicarbonate, 0.15M 2-mercaptoethanol and 10% fetal bovine serum (Hyclone, Inc., Logan, UT), were first induced by incubation in the presence of 50U/mL recombinant mouse  $\gamma$ -interferon (Genzyme, Cambridge, MA) for 24h prior to assay. 20 Induced cells were then mechanically collected and centrifuged at 500 x g at 4°C and then resuspended in 50mL RPMI 1640 medium (without supplements), re-centrifuged and again resuspended in RPMI 1640 medium (without supplements). The cells were counted and their concentration 25 adjusted to  $2 \times 10^5$  cells/mL and 100  $\mu$ L aliquots were added to each well of a 96-well microtitre plate. The cells were then incubated for about 15 hours with *E. coli* O113 LPS (Control Standard, Assoc. of Cape Cod, Woods Hole, MA), which was added in 100  $\mu$ L/well aliquots at a concentration of 1 ng/mL 30 in serum-free RPMI 1640 medium (this concentration being the result of titration experiments in which LPS concentration was varied between 50

pg/mL and 100 ng/mL). This incubation was performed in the absence or presence of peptides in varying concentrations between 25ng/mL and 50 $\mu$ g/mL. Recombinant human rBPI<sub>21</sub> also designated rBPI<sub>21</sub> $\Delta$ cys, which is rBPI 1-193, with alanine substituted at position 132 for cysteine [see co-owned U.S. Patent No. 5,420,019] was used as a positive control at a concentration of 1  $\mu$ g/mL. Cell proliferation was quantitatively measured by the addition of 1  $\mu$ Ci/well [<sup>3</sup>H]-thymidine 5 hours after the time of initiation of the assay. After the 15-hour incubation, labeled cells were harvested onto glass fiber filters with a cell harvester (Inotech Biosystems, INB-384, Sample Processing and Filter Counting System, Lansing, MI.).

The LPS-mediated inhibition of RAW 264.7 cell proliferation is dependent on the presence of LBP, as added to the reaction mixture either as a component of serum or as recombinant LBP (at a concentration of 1  $\mu$ g/mL). Different patterns of peptide behavior are observed in the assay. The Domain III derived anti-fungal peptides with LPS-neutralizing activity according to the present invention generally did not exhibit an IC<sub>50</sub> at the concentrations tested, unlike other XMP peptides including LPS-neutralizing peptides that are not anti-fungal, as described in co-owned and co-pending U.S. applications Serial Nos. 08/209,762 and 08/306,473. For example, XMP.5 displayed an EC<sub>50</sub> (*i.e.*, the peptide concentration at which the growth inhibitory effect of LPS was reversed by 50%) of  $5.3 \pm 0.6 \mu\text{g/mL}$ ; however, an IC<sub>50</sub> (*i.e.*, the peptide concentration at which RAW cell growth was inhibited by 50% from the value without added LPS or peptide) was not observed at the concentrations tested. The results of a representative assay of exemplary Domain III derived anti-fungal peptides are shown in Figure 8. The LPS-neutralizing activities of the purified anti-fungal peptides XMP.327 (open squares), XMP.332 (closed squares), XMP.333 (open triangles) and XMP.337 (closed triangles) are shown in Figure 8. Also shown as a positive control is the activity of rBPI<sub>21</sub>. Results from representative peptides tested with this assay are shown in Table 4.

TABLE 4

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>In Vitro</i> LPS Neutralization	
			EC <sub>50</sub> <sup>a</sup> µg/ml	IC <sub>50</sub> <sup>b</sup> µg/ml
XMP.97P (31)	148-161, K @ 152 (G)	98	3.69 ± 0.46	>25
XMP.127 (47)	148-161, F @ 153 (W)	63	10.77 ± 1.34	NA
XMP.284P (117)	149-161, K @ 152 (G)	96	4.72 ± 0.08/ 3.57 ± 0.09	NA/ >50
XMP.286P (119)	150-161, K @ 152 (G)	80	4.68 ± 0.26	NA
XMP.288P (121)	150-160, K @ 152 (G)	94	0.87 ± 0.06	>25
XMP.295P (128)	150-158, K @ 152 (G)	NT	3.69 ± 0.12	>25
XMP.303P (136)	153-160	98	11.79 ± 0.85	NA
XMP.327P (160)	K - K - 153 - 157 - K - K	94	11.92 ± 0.09	NA
XMP.330 (161)	153-156	95	>50	NA
XMP.331P (162)	† K - K - 153 - 157 - K - K	96	14.11 ± 0.35	NA



TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>In Vitro</i> LPS Neutralization	
			EC <sub>50</sub> <sup>a</sup> µg/ml	IC <sub>50</sub> <sup>b</sup> µg/ml
XMP.332P (163)	K <sub>D</sub> - K <sub>D</sub> - L <sub>D</sub> - Q <sub>D</sub> - I <sub>D</sub> - L <sub>D</sub> - W <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	98	5.65 ± 0.16	NA
XMP.333P (164)	K <sub>D</sub> - K - 153 - 157 - K - K	98	>25	NA
XMP.334P (165)	P <sub>D</sub> - K - K - 153 - 157 - K - K	89	NA	NA
XMP.335P (166)	P - K - 153 - 157 - K - K	98	NA	NA
XMP.336P (167)	R - R - 153 - 157- R - R	97	NA	NA
XMP.337P (168)	H - H - 153 - 157 - H - H	94	>50	NA
XMP.338 (169)	ORN - ORN - 153 - 157 - ORN - ORN	74	>25	NA
XMP.339P (170)	DAB - DAB - 153 - 157 - DAB - DAB	98	NA	NA

TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	EC <sub>50</sub> <sup>a</sup> µg/ml	IC <sub>50</sub> <sup>b</sup> µg/ml	<i>In Vitro</i> LPS Neutralization
XMP.340P (171)	p-amino-F - p-amino-F - 153 - 157 - p-amino-F - p- amino-F	94	> 50	NA	
XMP.341P (172)	PYR - PYR - 153 - 157 - PYR - PYR	99	> 50/ > 50	NA/NA	
XMP.342 (173)	K <sub>D</sub> - K <sub>D</sub> - 153 - 157 - K <sub>D</sub> - K <sub>D</sub>	72	> 50	NA	
XMP.342P (173)	K <sub>D</sub> - K <sub>D</sub> - 153 - 157 - K <sub>D</sub> - K <sub>D</sub>	97	NA	NA	
XMP.351P (182)	K - K - 153 - 158 - K - K	98	8.47 ± 0.71	NA	
XMP.352P (183)	K - K - 153 - 161	98	2.34 ± 0.38	NA	
XMP.353P (184)	P - 153 - 161*	99	4.42 ± 0.56	NA	
XMP.355P (186)	P - 153 - 161	99	1.08 ± 0.05	NA	

TABLE 4 (continued)

Peptide (SEQ ID NO:)	Peptide Amino Acid Segment	HPLC % Purity	<i>In Vitro</i> LPS Neutralization	
			EC <sub>50</sub> <sup>a</sup> µg/ml	IC <sub>50</sub> <sup>b</sup> µg/ml
XMP.363P (194)	K <sub>D</sub> - W <sub>D</sub> - 154 - 159 - K <sub>D</sub> - K <sub>D</sub>	97	>50	NA
XMP.365P (196)	K <sub>D</sub> - W <sub>D</sub> - L <sub>D</sub> - I <sub>D</sub> - Q <sub>D</sub> - L <sub>D</sub> - F <sub>D</sub> - H <sub>D</sub> - K <sub>D</sub> - K <sub>D</sub>	97	0.52 ± 0.07	>25

<sup>a</sup> NA for EC<sub>50</sub> means no evidence neutralization of LPS at up to 50 µg/ml  
<sup>b</sup> NA for IC<sub>50</sub> means no evidence of decreased RAW cell growth at up to 50 µg/ml  
<sup>c</sup> NT = not tested

Domain III derived peptides are also tested for LPS neutralizing efficacy in an *in vivo* mouse experimental endotoxemia model. Groups of 15 mice were administered an intravenous injection of endotoxin (*E. coli* O111:B4, Sigma Chemical Co., St. Louis, MO) at a LD<sub>90</sub> dosage of 20 mg/kg. This was followed by a second intravenous injection of the peptide to be tested. Injections of saline were used in negative control mice. The animals were observed for 7 days and mortality recorded. The efficacy of the peptides was measured by a decrease in endotoxemia-associated mortality in peptide-injected mice as compared with control mice. XMP.284 is a representative peptide active in this murine model. As shown in Figure 7, significant protection was observed with a 0.5 mg/kg dose of XMP.284, while at a 1 mg/kg dose, 14 of 15 animals were protected, and a 3 mg/kg dose was effective to protect all treated animals (100% survival). No animals survived in the saline control group.

### Example 8

#### PEPTIDE FORMULATIONS

This example addresses peptide formulations. A representative Domain III derived peptide XMP.284 was evaluated for stability in liquid formulations containing buffered saline solutions and to elucidate breakdown mechanisms, if any, that might be common to such peptides.

The lyophilized peptide was dissolved to a concentration of 1 mg/mL in three different buffers. The three formulation buffers used were (a) 10 mM solution acetate, 150 mM sodium chloride pH 4, (b) 10 mM sodium acetate, 150 mM sodium chloride pH 5 and (c) 10 mM sodium acetate, 150 mM sodium chloride pH 6. The formulated peptide samples were incubated at 4°C and 37°C. At each time point, samples were withdrawn from each vial and assayed by C18 reverse phase HPLC, absorbance at 280 nm, and SDS-PAGE. The study was conducted for 50 days.

A 0.46 x 25 cm Vydac C18 column (cat no. 218TP54) was used on a Shimadzu HPLC system. The column was run in binary gradient mobile phases: A = Water + 0.05 % TFA, B = acetonitrile + 0.05 % TFA. Chromatographic conditions were as follows: wavelength = 229 nm; flowrate = 1 mL/min; injection volume = 50  $\mu$ L; run time = 37 minutes; gradient = 20% B to 40% B in 20 minutes; AUFS = 0.1 for XMP.284; concentration of sample = 3.5  $\mu$ g per 50  $\mu$ L injection volume. In preparation for the C18 assay, the samples withdrawn from the vials were diluted 16-fold with 0.05 % TFA in water. All samples were filtered through Acrodisc 4 prior to analysis.

Samples were analyzed by SDS polyacrylamide gel electrophoresis, run on Novex 10-20% tricine precast gels (Novex, La Jolla, CA, EC6625). Samples were mixed with non-reducing sample loading buffer (Novex LC1676, 2x) and heated at 95°C for two minutes. After cooling, samples were run on the gel and the gels were stained with Coomassie Blue. In addition, samples were analyzed spectrophotometrically. For this, samples withdrawn at each time point were diluted 6-fold with Millipore water and absorbance was measured at 280 nm and scanning from 210 nm to 340 nm using a Shimadzu UV 160 spectrophotometer. All samples were filtered prior to absorbance measurement(s).

XMP.284 was soluble in water and unbuffered saline. XMP.284 was also soluble in 10 mM sodium phosphate, 150 mM sodium chloride pH 7. The peptide remained soluble in the phosphate buffer at 40°C for 1 hour and then 55°C for 1 hour. There was very little product loss, as measured by absorbance at 280 nm, in 0.15 M saline buffered with 10 mM acetate at pH 4, 5 or 6. The real time stability study at 4°C showed that product concentration was unchanged. Even the accelerated stability study at 37°C showed that greater than 95 % of product concentration was maintained and that only low levels (less than 0.5 % at 50 days) of new HPLC peaks accumulated with time at 37°C in the acetate buffered saline formulations. Given the substantial stability exhibited by the Domain III derived peptide as

tested, additional excipients may not be necessary but may be desired to further enhance long-term stability and/or activity.

Numerous modifications and variations in the practice of the invention are expected to occur to those skilled in the art upon consideration of the foregoing description on the presently preferred embodiments thereof. Consequently the only limitations which should be placed upon the scope of the present invention are those that appear in the appended claims.

10

15

20

25

30